WO2024056631A1 - S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases - Google Patents
S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases Download PDFInfo
- Publication number
- WO2024056631A1 WO2024056631A1 PCT/EP2023/074961 EP2023074961W WO2024056631A1 WO 2024056631 A1 WO2024056631 A1 WO 2024056631A1 EP 2023074961 W EP2023074961 W EP 2023074961W WO 2024056631 A1 WO2024056631 A1 WO 2024056631A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferon
- subject
- ifn
- type
- receptor modulator
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 145
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 85
- 201000010099 disease Diseases 0.000 title claims abstract description 82
- 230000001404 mediated effect Effects 0.000 title claims abstract description 60
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title abstract description 9
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title abstract description 9
- 108010050904 Interferons Proteins 0.000 claims abstract description 427
- 102000014150 Interferons Human genes 0.000 claims abstract description 426
- 229940079322 interferon Drugs 0.000 claims abstract description 425
- 229940075993 receptor modulator Drugs 0.000 claims abstract description 196
- 230000004547 gene signature Effects 0.000 claims abstract description 157
- 150000003839 salts Chemical class 0.000 claims abstract description 143
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract description 41
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract description 41
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 35
- 102000008070 Interferon-gamma Human genes 0.000 claims abstract description 34
- 229960003130 interferon gamma Drugs 0.000 claims abstract description 34
- 230000002265 prevention Effects 0.000 claims abstract description 12
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 claims description 155
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims description 155
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 claims description 155
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 153
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims description 147
- KJKKMMMRWISKRF-FQEVSTJZSA-N (2s)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol Chemical compound CC1=C(OC[C@@H](O)CO)C(CC)=CC(C=2N=C(ON=2)C=2C=C(N=C(OC)C=2)C2CCCC2)=C1 KJKKMMMRWISKRF-FQEVSTJZSA-N 0.000 claims description 145
- 108090000623 proteins and genes Proteins 0.000 claims description 145
- 229950004741 cenerimod Drugs 0.000 claims description 141
- 238000000034 method Methods 0.000 claims description 134
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims description 127
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims description 127
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims description 121
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims description 121
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims description 121
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims description 120
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims description 120
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 claims description 119
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 claims description 119
- 230000014509 gene expression Effects 0.000 claims description 110
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims description 97
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims description 97
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 claims description 66
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 claims description 66
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims description 61
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims description 59
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 claims description 52
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 claims description 52
- 206010025135 lupus erythematosus Diseases 0.000 claims description 36
- 239000012472 biological sample Substances 0.000 claims description 35
- 230000009467 reduction Effects 0.000 claims description 35
- 101001067396 Homo sapiens Phospholipid scramblase 1 Proteins 0.000 claims description 34
- 102100034627 Phospholipid scramblase 1 Human genes 0.000 claims description 34
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 230000009266 disease activity Effects 0.000 claims description 27
- 238000009826 distribution Methods 0.000 claims description 27
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 claims description 22
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 claims description 22
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 claims description 22
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 claims description 22
- 102100039621 Epithelial-stromal interaction protein 1 Human genes 0.000 claims description 22
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 claims description 22
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 claims description 22
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 claims description 22
- 101000814134 Homo sapiens Epithelial-stromal interaction protein 1 Proteins 0.000 claims description 22
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 claims description 22
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 claims description 22
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 claims description 22
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 claims description 22
- 101000828739 Homo sapiens SPATS2-like protein Proteins 0.000 claims description 22
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 claims description 22
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 claims description 22
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 claims description 22
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 claims description 22
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 claims description 22
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 claims description 22
- 102100023521 SPATS2-like protein Human genes 0.000 claims description 22
- 102100032855 Sialoadhesin Human genes 0.000 claims description 22
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 claims description 22
- 230000002902 bimodal effect Effects 0.000 claims description 22
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 claims description 17
- 101000864662 Homo sapiens Probable ATP-dependent RNA helicase DHX58 Proteins 0.000 claims description 17
- 101000735459 Homo sapiens Protein mono-ADP-ribosyltransferase PARP9 Proteins 0.000 claims description 17
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 claims description 17
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 claims description 17
- 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 claims description 17
- 102100034930 Protein mono-ADP-ribosyltransferase PARP9 Human genes 0.000 claims description 17
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 claims description 17
- KIHYPELVXPAIDH-HNSNBQBZSA-N 1-[[4-[(e)-n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-HNSNBQBZSA-N 0.000 claims description 13
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical group C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 13
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 claims description 13
- 229950008141 ozanimod Drugs 0.000 claims description 12
- 238000012935 Averaging Methods 0.000 claims description 11
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 11
- 229950009275 ponesimod Drugs 0.000 claims description 11
- 229950005693 siponimod Drugs 0.000 claims description 11
- 201000002481 Myositis Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 claims description 8
- 229940069604 etrasimod Drugs 0.000 claims description 7
- 208000027066 STING-associated vasculopathy with onset in infancy Diseases 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- IINUNQPYJGJCJI-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol Chemical compound C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 IINUNQPYJGJCJI-UHFFFAOYSA-N 0.000 claims description 5
- JVCPIJKPAKAIIP-UHFFFAOYSA-N 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol Chemical compound CCCCCCCOC1=CC=C(CCC(N)(CO)CO)C=C1C(F)(F)F JVCPIJKPAKAIIP-UHFFFAOYSA-N 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 229950004817 amiselimod Drugs 0.000 claims description 5
- 229940069679 mocravimod Drugs 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000033237 Aicardi-Goutières syndrome Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 206010058105 Neutrophilic dermatosis Diseases 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 abstract description 32
- 102100037850 Interferon gamma Human genes 0.000 abstract 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 76
- 229940068196 placebo Drugs 0.000 description 76
- 239000003814 drug Substances 0.000 description 37
- 230000004044 response Effects 0.000 description 37
- 239000000523 sample Substances 0.000 description 37
- 229940079593 drug Drugs 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 206010003246 arthritis Diseases 0.000 description 25
- 238000012216 screening Methods 0.000 description 21
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 230000002459 sustained effect Effects 0.000 description 15
- 238000005251 capillar electrophoresis Methods 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 238000012790 confirmation Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 229950010117 anifrolumab Drugs 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 229940124624 oral corticosteroid Drugs 0.000 description 12
- 210000004789 organ system Anatomy 0.000 description 11
- 108700039887 Essential Genes Proteins 0.000 description 10
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 10
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 10
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 10
- 101150103227 IFN gene Proteins 0.000 description 10
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 9
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 9
- 238000011321 prophylaxis Methods 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- 208000010201 Exanthema Diseases 0.000 description 8
- 241000219061 Rheum Species 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 231100000360 alopecia Toxicity 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000003246 corticosteroid Substances 0.000 description 8
- 201000005884 exanthem Diseases 0.000 description 8
- 229960000556 fingolimod Drugs 0.000 description 8
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 8
- 230000014725 late viral mRNA transcription Effects 0.000 description 8
- 206010037844 rash Diseases 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- IXZOHGPZAQLIBH-NRFANRHFSA-N (3s)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N([C@@H]2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-NRFANRHFSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 7
- 229960004618 prednisone Drugs 0.000 description 7
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 229960002170 azathioprine Drugs 0.000 description 6
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 229960003270 belimumab Drugs 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 239000003862 glucocorticoid Substances 0.000 description 6
- 229950009627 iberdomide Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 6
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 6
- 229960004866 mycophenolate mofetil Drugs 0.000 description 6
- 229960000951 mycophenolic acid Drugs 0.000 description 6
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 206010073960 CANDLE syndrome Diseases 0.000 description 4
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 4
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 4
- 241000722921 Tulipa gesneriana Species 0.000 description 4
- 239000003430 antimalarial agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229960003677 chloroquine Drugs 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 4
- 229960004171 hydroxychloroquine Drugs 0.000 description 4
- 201000002364 leukopenia Diseases 0.000 description 4
- 231100001022 leukopenia Toxicity 0.000 description 4
- 229960000901 mepacrine Drugs 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 208000017502 proteosome-associated autoinflammatory syndrome Diseases 0.000 description 4
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 3
- 230000000078 anti-malarial effect Effects 0.000 description 3
- 230000003460 anti-nuclear Effects 0.000 description 3
- 229940033495 antimalarials Drugs 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000009597 pregnancy test Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000006740 Aseptic Meningitis Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000016918 Complement C3 Human genes 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000009139 Gilbert Disease Diseases 0.000 description 2
- 208000022412 Gilbert syndrome Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 description 2
- 101150106931 IFNG gene Proteins 0.000 description 2
- 102000017182 Ikaros Transcription Factor Human genes 0.000 description 2
- 108010013958 Ikaros Transcription Factor Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 2
- 206010027201 Meningitis aseptic Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 206010068786 Overlap syndrome Diseases 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 208000011235 central nervous system lupus Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 108010085650 interferon gamma receptor Proteins 0.000 description 2
- 230000010468 interferon response Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 229940125468 saphnelo Drugs 0.000 description 2
- 229950010077 sifalimumab Drugs 0.000 description 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- LPAUOXUZGSBGDU-ULCCENQXSA-N (5z)-5-[[3-chloro-4-[(2r)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=NCCC)S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-ULCCENQXSA-N 0.000 description 1
- JNLIKIBISICTMS-PEJBKAKVSA-N (e)-but-2-enedioic acid;1-[[4-[(e)-n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound OC(=O)\C=C\C(O)=O.CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1.CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 JNLIKIBISICTMS-PEJBKAKVSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- HAOOCAKHSFYDBU-BDQAORGHSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile;hydrochloride Chemical class Cl.C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 HAOOCAKHSFYDBU-BDQAORGHSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000006547 Central Nervous System Lupus Vasculitis Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- 101000713600 Homo sapiens T-box transcription factor TBX22 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 1
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010061285 Mental disorder due to a general medical condition Diseases 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 201000000668 Mobitz type II atrioventricular block Diseases 0.000 description 1
- 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 102100032783 Protein cereblon Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037457 Pulmonary vasculitis Diseases 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 description 1
- 102100036839 T-box transcription factor TBX22 Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- -1 Tascenso ODT Chemical compound 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000029265 Type 1 interferonopathy Diseases 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 229940126219 Zeposia Drugs 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000027093 acute inflammatory demyelinating polyradiculoneuropathy Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940125488 anifrolumab fnia Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 208000010353 central nervous system vasculitis Diseases 0.000 description 1
- 201000008191 cerebritis Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000000495 immunoinflammatory effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000002003 mononeuritis multiplex Diseases 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229940125450 ponvory Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229950010316 rontalizumab Drugs 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 201000002931 third-degree atrioventricular block Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- S1Pi receptor modulators for use in the treatment of type 1 IFN mediated diseases
- the present invention relates to a S1Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a type 1 interferon mediated disease in a subject that has a high type 1 interferon (IFN-1) gene signature score or elevated levels of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in blood plasma.
- IFN-1 type 1 interferon
- IFN-a interferon-alpha
- IFN-y interferon-gamma
- Sphingosine 1 -phosphate is a lipid mediator formed by the metabolism of sphingomyelin.
- S1 P is secreted into the extracellular environment and signals via G protein coupled S1 P receptors including the S1 P1 receptor which plays an important role in lymphocyte trafficking [Mendelson, K. et al., Development 2014, 141 , 5-9, PMID:24346695],
- S1 P1 receptor modulators are approved for the treatment of multiple sclerosis and Inflammatory Bowel Disease and are being investigated in further inflammatory diseases involving lymphocyte driven inflammatory processes [Burg, N. et al., Nat Rev Rheumatol. 2022, 18(6), 335-351 , PMID:35508810],
- (S)-3- ⁇ 4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1 ,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy ⁇ -propane-1 ,2-diol (hereinafter also referred to as “COMPOUND” or “cenerimod”) is a potent, selective, and orally active S1 P1 receptor modulator which prevents the egress of lymphocytes from secondary lymphoid organs into the vascular circulation, via internalization of the S1 P1 receptor.
- its immunomodulatory role in autoimmune diseases may be of benefit in treating such diseases in which lymphocytes play an important role in propagating disease.
- SLE systemic lupus erythematosus
- cenerimod reduced both B and T lymphocytes in the circulation confirming the mode of action (Hermann V, et al. Lupus Science & Medicine 2019;6:e000354. doi:10.1136/lupus-2019-000354). Furthermore, cenerimod reduced interferon (IFN)-associated proteins in plasma [Strasser, DS et al., RMD Open 2020, 6, e001261 , PMID: 32917831],
- IFNs are central effector molecules produced in large amounts during an immune response to infection, activating defense mechanisms and resulting in the inhibition of microbial replication.
- Type 1 IFNs are the largest group and comprise several classes and subclasses. Almost all cells can produce IFN-a and I FN-
- IFN-x is the only type 2 IFN and is mainly produced by NK cells and T cells of the immune system [McNab, F. et al., Nat Rev Immunol 2015, 15, 87-103, PMID:25614319; Rbnnblom, L. et al., Lupus Sci Med 2019, 6, e000270, PMID:31497305; Colonna, M. et al., Current Opinion Immunol 2002, 14, 373-379, PMID:11973137],
- Type-1 IFNs signal through a heterodimeric transmembrane receptor composed of the subunits IFNAR1 and IFNAR2, broadly expressed across multiple cell types.
- type 2 IFN engage with the heterodimer IFNGR1 and IFNGR2.
- Both IFNAR and IFNGR complexes recruit JAK kinase family members.
- IFNAR recruits TYK2 and JAK1 while IFNGR recruits JAK1 and JAK2. This leads to subsequent STAT1 and STAT2 phosphorylation and the subsequent translocation of the signaling pathway transcription factors into the nucleus.
- IFNAR recruits TYK2 and JAK1
- IFNGR recruits JAK1 and JAK2.
- STAT1 and STAT2 phosphorylation and the subsequent translocation of the signaling pathway transcription factors into the nucleus.
- Nucleic acids are sensed among other cells by plasmacytoid dendritic cells (pDCs), which are thought to be a key cell type producing type 1 IFNs in SLE.
- pDCs plasmacytoid dendritic cells
- IFN Type 1 Celia, M. et al., Nature Med 1999, 5(8), 919-923, PMID:10426316
- other cell types may be involved in IFN production in SLE including keratinocytes, endothelial cells, fibroblasts and monocytes, NK cells, B cells and T cells.
- genetic risk factors have been identified in SLE that are associated with IFN production or responses to IFNs further supporting the hypothesis that perturbations in IFN regulation may contribute to SLE [Deng, Y. et al., Curr Rheumatol Rep 2017, 19, 68 PMID:28983873, Catalina, MD. et al., Communications Biology 2019, 2(140), https://doi.Org/10.1038/S42003-019-0382-x, PMID:31044165],
- IFN-1 signature reflects IFN-regulated genes, meaning that those genes are upregulated due to the biological activity of type 1 IFNs.
- Subsequent studies have demonstrated between 50 and 80% of SLE patients show a consistent presence of an IFN- 1 signature from the blood and this is stable over time [Northcott, M.
- IFN signaling has broad and wide-ranging effects on the body and increased IFN production may be linked to potential disease manifestations in patients with SLE, the principal ones are summarized below.
- IFN has also been shown to be high in the kidney tissue suggesting a strong link of IFN with kidney damage [Castellano, G. et al., Arthritis Research Therapy 2015, 17, 72, PMID:25889472],
- IFNs participate in SLE disease, however the association of a blood IFN signature and clinical disease characteristics is not limited to any one manifestation. Further the IFN signature does not distinguish between high and low disease activity [Kennedy, WP. et al., Lupus Sci Med 2015, 2, e000080, PMID:25861459], as defined by various criteria, but can predict the subsequent disease severity over time [Mai, L. et al., Arthritis Research Therapy 2021 , 23, 29, PMID: 33451338],
- IFN-1 gene signature Data on the distribution of type 1 IFN gene signature high vs IFN signature low within the general SLE population is somewhat limited but reports have placed it in the range of 60- 80% [Psarras, A. et al., Rheumatology 2017, 56, 1662-1675, PMID:28122959], An important property of the IFN-1 gene signature is the bimodal distribution in patients with SLE allowing separation into high or low IFN-1 gene signature strata [El-Sherbiny, YM.
- IFN-1 high patients patients with a high type 1 interferon gene signature score (“IFN-1 high patients”) were more likely to be receiving higher immunosuppressants and glucocorticoids than IFN-1 low patients (75% vs 50%), were likely to be younger and of Asian ancestry [Northcott, M.
- IFNs The prominent role of IFNs in SLE has prompted efforts to target this pathway as a means of treating SLE and has been investigated in clinical trials.
- a prime example is anifrolumab, an antibody targeting the IFN-1 receptor.
- further potential therapies have been investigated for their potential ability to modulate IFN-1 gene signature score.
- phase 3 studies of anifrolumab confirmed the suppression of the interferon signature in patients with IFN-1 high at baseline seen in a phase 2 trial, although the association of this effect with clinical efficacy was not demonstrated.
- TULIP 1 the efficacy of anifrolumab measured with a (SLE) Responder Index (SRI-4) [Furie, R. et al. Arthritis Rheumatism 2009, 61 (9), 1143-1151 , PMID: 19714615] (placebo adjusted) in patients with IFN-1 high at baseline is modest, i.e., 6 percentage points.
- TULIP 2 the efficacy of anifrolumab (placebo adjusted) measured with SRI-4 is numerically higher in patients with IFN-1 high at baseline than in patients with IFN-1 low, i.e., 17.3 and 11.2 percentage points, respectively.
- the pooled phase 3 studies TULIP 1 & 2 allows comparisons of greater sample size for the IFN-1 low group, (i.e., 122 patients in IFN-1 low treated with 300 mg or placebo, 60 and 62 patients, respectively) [Vital, EM.
- Iberdomide is a high affinity cereblon ligand that promotes proteasomal degradation of transcription factors Ikaros and Aiolos.
- Aiolos is a B cell modulator and is required for maturation of plasma cells.
- Ikaros is required for development of B cells and plasmacytoid pDCs, which are important producers of IFN-a [Lipsky, PE. et al., Ann Rheum Dis 2022, 81 , 1136-1142, PMID:35477518],
- Iberdomide doses of 0.15, 0.30 and 0.45 mg were investigated against placebo in a phase 2 study where 179 of 288 patients (62%) were IFN-1 high at baseline. This trial was not stratified according to gene signature at baseline, the highest proportion of IFN-1 high was in the 0.45 mg group (70%), and the lowest in the placebo group (58%) [Merrill, JT. et al., N Engl J Med 2022, 386, 1034-1045, PMID:35294813],
- the highest SRI-4 response (the primary end point) had occurred in 44 of 81 patients (54%) receiving the 0.45-mg dose of iberdomide and in 29 of 83 patients (35%) receiving placebo (adjusted difference, 19.4 percentage points).
- Iberdomide and placebo did not have meaningful differences with respect to most secondary end points.
- the responses occurred in 34 of 57 patients (60%) in the 0.45 mg iberdomide group vs 16 of 48 patients (33%) in the placebo group.
- phase 2 SLE patients with an IFN-1 high status at baseline manifested a significant reduction in the IFN signature as a result of active treatment, whereas those with low baseline IFN signature did not [[Lipsky, PE. et al., Ann Rheum Dis 2022, 81 , 1136-1142, PMID:35477518], Treatment with iberdomide was associated with a significant, dosedependent reduction in pDCs and mDCs, which are thought to be primary sources of type 1 IFNs.
- Rontalizumab despite targeting the IFN-1 pathway, was found to be more efficacious in IFN-1 low patients (Kalunian, K. et al., Ann Rheum Dis 2016, 75, 196-202, PMID: 26038091). This further highlights the complexity to identify responder patients’ subgroups.
- Sifalimumab is a fully human, immunoglobulin G1 K monoclonal antibody that binds to and neutralizes most IFN-a subtypes. It was developed by AstraZeneca and its development was discontinued in favor of anifrolumab. Earlier clinical trials of sifalimumab have established its suppression of IFN-a-induced genes and have suggested favorable effects on clinical outcome measures [Petri, M. et al., Arthritis Rheumatism 2013, 65(4), 1011- 1021 , PMID:23400715],
- S1 P modulators in modulating IFN associated proteins in the context of SLE was recently investigated by Strasser et al. Efficacy in an MRL/lpr mouse model of SLE was demonstrated with a decrease in lymphocytes in the periphery and an improvement in survival. Further, a small exploratory study involving 13 patients diagnosed with SLE were treated with cenerimod for a period of 12 weeks. A large heterogeneity in IFN associated biomarkers between the patients in the study was observed and cenerimod treatment led to a trend in the reduction of IFN associated biomarkers [Strasser, DS et al., RMD Open 2020, 6, e001261 , PMID: 32917831],
- Figure 1 shows:
- the whiskers indicate the minimum and maximum range.
- a decrease in the mean value of IFN alpha protein in the cenerimod 4mg group is observed after 6 months compared to baseline, whereas a slight elevation in the mean value is observed over 6 months in the placebo group.
- the whiskers indicate the minimum and maximum range.
- a decrease in the mean value of IFN gamma protein in the cenerimod 4mg group is observed between baseline and after 6 months treatment, whereas a slight elevation in the mean value is observed over 6 months in the placebo group.
- a first embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease in a subject, wherein the subject has a high type 1 interferon (IFN-1) gene signature score.
- IFN-1 type 1 interferon
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 1), wherein the subject has a high type 1 interferon (IFN-1) gene signature score at treatment onset.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLS
- Group a) is disclosed in WO 2020/084591 ; group b) in WO 2022/074123 and in Yao Y, et al. Human Genomics and Proteomics 2009; article ID 374312, doi:10.4061/2009/374312; groups c) to h) in WO 2011/028933 and in Furie R, et al. Arthritis & Rheumatology 2017; 69(2) 376-386; group i) in Westra H-J, et al. Nature Genetics 2013; 45(10) 1238-1243, doi:10.1038/ng.2756; group j) in Niewold, T et al. Genes and Immunity 2007; 8 492-502, doi: 10.1038/sj.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2,
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on the type 1 interferon-associated genes EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5.
- the type 1 interferon gene signature score of a subject can be calculated according to any of the methods given in WO 2011/028933, WO 2020/084591 , Furie R, et al. Arthritis & Rheumatology 2017; 69(2) 376-386 or Northcott M, et al. Lupus Science & Medicine 2022;9:e000625; doi:10.1136/lupus-2021 -000625. Northcott et al.
- the IFN-1 gene signature score of a subject describes especially a method to calculate the IFN-1 gene signature score of a subject based on the 4 genes RSAD2, IFI27, IFIT1 , and HERC5 and further discloses an IFN-1 gene signature score cutoff value of -0.5 between subjects having a low and a high IFN-1 gene signature score.
- Northcott et al. further refers to an IFN-1 test that is commercially available from DxTerity Diagnostics Inc.
- the type 1 interferon gene signature score of a subject can be calculated by the method originally developed by DxTerity Diagnostics Inc.
- RNA gene expression levels of the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5 in a blood sample of a subject (for instance by measuring respective peak height in capillary electrophoresis electropherograms); (ii) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject; (iii) calculating the binary logarithm (log 2 ) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof; (iv) calculating the normalized expression for each of the four type 1 interferon- associated genes according to Formula (I); and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the four type 1 interferon-associated genes.
- RNA gene expression levels of the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5 in a blood sample of a subject
- IFN-1 gene signature An important property of the IFN-1 gene signature is the bimodal distribution in subjects with systemic lupus erythematosus (SLE) allowing separation into subjects with a high type 1 interferon (IFN-1) gene signature score (IFN-1 high subjects) and subjects with a low score (IFN-1 low subjects) [El-Sherbiny, YM.
- SLE systemic lupus erythematosus
- Subjects having a high IFN-1 gene signature score can be defined as subjects with an IFN-1 gene signature score above a threshold value (or alternatively “cut-off value”); those having a low IFN-1 gene signature score can be defined as subjects with an IFN-1 gene signature score at or below the threshold value.
- the threshold or cut-off value can be defined in accordance with any of the methods known in the art (for instance WO 2011/028933 or Northcott M, et al. Lupus Science & Medicine 2022;9:e000625; doi:10.1136/lupus-2021 -000625).
- the threshold I cut-off value can be defined relative to the IFN-1 gene signature score of healthy humans: for instance, the threshold I cut-off value may be any IFN-1 gene signature score value between 1 .8 to 4.0 (notably 2.0 to 3.0) standard deviations above the arithmetic mean value from at least 20 (notably at least 200) healthy humans.
- the threshold I cut-off value of the IFN-1 gene signature score may be defined as 2 standard deviations above the arithmetic mean value from at least 100 (notably at least 300) healthy humans.
- the IFN-1 gene signature scores of subjects (especially patients) and of healthy humans (for determination of the cut-off value) are calculated using the same method of IFN-1 gene signature score determination.
- Abedi et al. (DxTerity) have compared in a study the relative performance of four different IFN gene signatures in a cohort of 687 participants with self-reported systemic lupus erythematosus (SLE).
- SLE systemic lupus erythematosus
- the frequently used 4-gene IFN signature of IFI27, IFI44, IFI44L, and RSAD2 identified 36.5% of the participants as IFN high and 63.5% as IFN low.
- IFN signatures Three other literature reported IFN signatures (IFI6, MX1 , IFIT1 , and HERC5; EIF2AK2, MX1 , and IFIT1 ; and EIF2AK2, IFI44, and IFIT1) provided similar classification results with participants being assigned to the same IFN sub-group (IFN high/IFN low) over 90% of the time, and nearly identical patient distributions; all four IFN gene signatures resulted in a similar bimodal IFN-1 gene signature score distribution as found with the 4 genes RSAD2, IFI27, IFIT1 , and HERC5 and shown in Fig. 1A (Abedi M et al. Annals of the Rheumatic Diseases 2018; 77 (Suppl.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 8), wherein the type 1 interferon gene signature score of the subject is at or above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
- the minimum of the bimodal distribution curve may be obtained by determining the number of SLE patients with a given type 1 interferon gene signature score as a function of the type 1 interferon gene signature score.
- the bimodal distribution curve may be based on the type 1 interferon gene signature scores of at least 50, of at least 100, of at least 200, or (preferably) of at least 300 SLE patients.
- the bimodal distribution curve may be obtained from current (e.g., from data collected less than 1 year ago) and/or from historical (e.g., from data collected more than 1 year ago) data on type 1 interferon gene signature scores in SLE patients.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 9), wherein the type 1 interferon gene signature score of the subject is at least 0.5 units, at least 1 unit, at least 2 units or at least 3 units (especially at least 1 unit) above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 8), wherein the subject has a type 1 interferon gene signature score that is higher than the type 1 interferon gene signature score of a (representative) healthy subject.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 8), wherein the type 1 interferon gene signature score of the subject is above a threshold value.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 12), wherein the threshold value is an IFN-1 gene signature score value that is selected from values between 1.8 to 4.0 (i.e.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 12), wherein the threshold value of the IFN-1 gene signature score is 2 standard deviations above the arithmetic mean value from at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 12), wherein the threshold value of the IFN-1 gene signature score is between -1.0 and 0 (especially about - 0.5).
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 12), wherein the threshold value of the IFN-1 gene signature score is -0.5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 16), wherein the type 1 interferon gene signature score of the subject is calculated (determined) by a method comprising the following steps:
- RNA gene expression levels of the type 1 interferon-associated genes (especially of RSAD2, IFI44, IFI44L, and IFI27; or of RSAD2, IFI27, IFIT1 , and HERC5; and notably of RSAD2, IFI27, IFIT1 , and HERC5) in a blood sample of a subject (notably by measuring respective peak height by capillary electrophoresis);
- Formula (I) and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the type 1 interferon-associated genes.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 3) to 16), wherein the type 1 interferon gene signature score of the subject is calculated (determined) by a method comprising the following steps:
- RNA gene expression levels of the type 1 interferon-associated genes (especially of RSAD2, IFI44, IFI44L, and IFI27; or of RSAD2, IFI27, IFIT1 , and HERC5; and notably of RSAD2, IFI27, IFIT1 , and HERC5) in a blood sample of a subject (notably by measuring respective peak height by capillary electrophoresis);
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with the S1 Pi receptor modulator), the method comprising: a) providing a biological sample (especially a blood sample or a serum sample, and notably a blood sample) from the subject; b) assaying gene expression of at least three (especially at least four) type 1 interferon- associated genes selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15,
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 19), wherein the subject has a type 1 interferon gene signature score that is higher than a threshold value at treatment onset and/or is higher than the type 1 interferon gene signature score in a biological sample from a healthy subject at treatment onset.
- the subject has a type 1 interferon gene signature score that is higher than a threshold value at treatment onset.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) or 20), wherein the biological sample is a blood sample.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44, and IFI44,
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, IFI44, IFI44
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein the type 1 interferon-associated genes for assaying gene expression are EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein the type 1 interferon-associated genes for assaying gene expression are RSAD2, IFI27, IFIT1 , and HERC5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 27), wherein the gene expression is assayed by capillary electrophoresis (especially capillary electrophoresis suitable for nucleotide analysis).
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 27), wherein the gene expression of the type 1 interferon-associated genes is assayed by measuring peak height in capillary electrophoresis electropherograms.
- the normalized expression values are calculated based on peak heights (especially peak heights in capillary electrophoresis electropherograms) of the respective genes by using Formula (I).
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 30), wherein the type 1 interferon gene signature score of the subject is at or above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
- the minimum of the bimodal distribution curve may be obtained by determining the number of SLE patients with a given type 1 interferon gene signature score as a function of the type 1 interferon gene signature score.
- the bimodal distribution curve may be based on the type 1 interferon gene signature scores of at least 50, of at least 100, of at least 200, or (preferably) of at least 300 SLE patients.
- the bimodal distribution curve may be obtained from current (e.g., from data collected less than 1 year ago) and/or from historical (e.g., from data collected more than 1 year ago) data on type 1 interferon gene signature scores in SLE patients.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 31), wherein the type 1 interferon gene signature score of the subject is at least 0.5 units, at least 1 unit, at least 2 units or at least 3 units (especially at least 1 unit) above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 30), wherein the threshold value is an IFN-1 gene signature score value that is selected from values between 1.8 to 4.0 (i.e.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 30), wherein the threshold value of the IFN-1 gene signature score is 2 standard deviations above the arithmetic mean value from at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 30), wherein the threshold value of the IFN-1 gene signature score is selected from values between -1.0 and 0 (especially about -0.5, and notably -0.5).
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 35), wherein the threshold value of the IFN-1 gene signature score is -0.5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with the S1 Pi receptor modulator), the method comprising: a) providing a biological sample (especially a blood sample or a serum sample, and notably a blood sample) from the subject; b) assaying gene expression of the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5 in the biological sample (especially by measuring peak height in capillary electrophoresis electropherograms); c) determining a normalised expression value of each assayed gene by (i) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in the biological sample of the subject; (ii) calculating the binary logarithm (log 2 ).
- Formula (II) d) calculating a type 1 interferon gene signature score by averaging the normalised expression values; and e) treating the subject with the S1 Pi receptor modulator when the type 1 interferon gene signature score of the subject is higher than a threshold value, wherein the threshold value is selected from values between -1.0 and 0 (especially -0.5).
- the normalized expression values are calculated based on peak heights of the respective genes by using Formula (I).
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with the S1 Pi receptor modulator) in a subject, wherein at least three (especially at least four) type 1 interferon-associated genes are upregulated in the subject (especially in a biological sample from the subject), wherein the type 1 interferon-associated genes are selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6 (especially IFI6,
- the upregulation of type 1 interferon-associated genes in the subject’s expression profile may be by any degree relative to that of a sample from a control (which may be from a sample that is not disease tissue of the subject or from a healthy person not afflicted with the type 1 interferon mediated disease) or may be relative to that of genes from the subject whose expression is not changed by the type 1 interferon mediated disease (so called housekeeping genes); especially relative to that of genes from the subject whose expression is not changed by the type 1 interferon mediated disease.
- a control which may be from a sample that is not disease tissue of the subject or from a healthy person not afflicted with the type 1 interferon mediated disease
- housekeeping genes especially relative to that of genes from the subject whose expression is not changed by the type 1 interferon mediated disease.
- the degree of upregulation may be at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 300%, or more that of the control or control sample.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 38), wherein the type 1 interferon-associated genes are upregulated in the subject at treatment onset.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44,
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, I
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three of the following type 1 interferon-associated genes are upregulated in the subject: EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three of the following type 1 interferon-associated genes are upregulated in the subject: RSAD2, IFI27, IFIT1 , and HERC5.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease in a subject, wherein the concentration/level of interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is elevated compared to a healthy subject.
- IFN-y interferon-gamma
- a subject wherein the concentration/level of interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is elevated compared to a healthy subject” means a subject having, and/or identified as having, and/or diagnosed as having (especially in blood plasma of the subject) a concentration/level of interferon-gamma (IFN- y) that is elevated compared to a healthy subject.
- IFN-y interferon-gamma
- a subject wherein the concentration/level of interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is elevated compared to a healthy subject” means a subject having, and/or identified as having, and/or diagnosed as having (especially in blood plasma of the subject) a concentration/level of interferon-gamma (IFN- y) that is higher than the concentration/level of interferon-gamma (IFN-y) in 95% of healthy volunteers in a statistically representative group of the healthy volunteers.
- IFN-y concentration/level of interferon-gamma
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease in a subject, wherein the subject has a concentration/level (especially a concentration/level in blood plasma) of interferon-gamma (IFN-y) above 9.5 pg/mL.
- a concentration/level especially a concentration/level in blood plasma
- IFN-y interferon-gamma
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease (that is responsive to treatment with the S1 Pi receptor modulator), the method comprising: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-gamma (IFN-y) in the biological sample; and c) treating the subject with the S1 Pi receptor modulator when the concentration/level of interferon-gamma (IFN-y) is elevated compared to the concentration/level of interferon- gamma (IFN-y) in a biological sample from a healthy subject and/or is above 9.5 pg/mL.
- a biological sample especially a plasma sample
- IFN-y concentration/level of interferon-gamma
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 48), wherein the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is/are elevated compared to a healthy subject.
- IFN-a interferon-alpha
- IFN-y interferon-gamma
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 48), wherein the subject has a concentration/level (especially a concentration/level in blood plasma) of interferon-alpha (IFN-a ) above 0.1 pg/mL and/or of interferon-gamma (IFN-y) above 9.5 pg/mL.
- IFN-a interferon-alpha
- IFN-y interferon-gamma
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method according to any one of embodiments 19) to 37), wherein the method further comprises: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the biological sample; and c) treating the subject with the S1 Pi receptor modulator when the concentration/level of interferon-alpha (IFN-a ) and/or of interferon-gamma (IFN-y) is elevated compared to the concentration/level in a biological sample from a healthy subject.
- a biological sample especially a plasma sample
- IFN-y interferon-gamma
- treatment of the subject with the S1 Pi receptor modulator according to dependent embodiment 51 requires both conditions to be fulfilled: (i) that the type 1 interferon gene signature score of the subject is higher than the respective threshold value and (ii) that the concentration/level of interferon-alpha (IFN-a ) and/or of interferon-gamma (IFN-y) is elevated compared to the concentration/level in a biological sample from a healthy subject.
- IFN-a interferon-alpha
- IFN-y interferon-gamma
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method according to any one of embodiments 19) to 37), wherein the method further comprises: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the biological sample; and c) treating the subject with the S1 Pi receptor modulator when the concentration/level of interferon-alpha (IFN-a ) is above 0.1 pg/mL and/or when the concentration/level of interferon-gamma (IFN-y) is above 9.5 pg/mL.
- a biological sample especially a plasma sample
- IFN-y interferon-gamma
- treatment of the subject with the S1 Pi receptor modulator according to dependent embodiment 52 requires both conditions to be fulfilled: (i) that the type 1 interferon gene signature score of the subject is higher than the respective threshold value and (ii) that the concentration/level of interferon-alpha (IFN-a ) is above 0.1 pg/mL and/or that the concentration/level of interferon-gamma (IFN-y) is above 9.5 pg/mL.
- IFN-a concentration/level of interferon-alpha
- IFN-y concentration/level of interferon-gamma
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 52), wherein the S1 Pi receptor modulator is selected from fingolimod, ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof (especially from ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof, and notably from ozanimod, siponimod, ponesimod, cenerimod, or a pharmaceutically acceptable salt thereof).
- Fingolimod (also known as FTY720, Gilenya, Tascenso ODT, 2-amino-2-[2-(4- octylphenyl)ethyl]propan-1 ,3-diol) is a S1 P receptor modulator that binds to several S1 P receptors.
- Fingolimod is used as a hydrochloride salt, is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and is available as hard capsules in strength of 0.25 mg and 0.5 mg.
- Fingolimod is used as a lauryl sulfate salt, is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and is available as orally disintegrating tablets in strength of 0.25 mg and 0.5 mg.
- Ozanimod (also known as RPC1063, Zeposia, 5-(3- ⁇ (1S)-1-[(2-hydroxyethyl)amino]-2,3- dihydro-1 /-/-inden-4-yl ⁇ -1 ,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile) is a S1 P receptor modulator that selectively binds to S1 Pi and S1 P 5 receptors.
- Ozanimod is used as a hydrochloride salt, is approved by the U.S.
- the recommended maintenance dosage is 0.92 mg orally once daily.
- Siponimod (also known as BAF312, MAYZENT, 1-[[4-[(1E)-1-[[[4-Cyclohexyl-3- (trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]-3-azetidinecarboxylic acid) is a dual S1 Pi and S1 P 5 receptor modulator.
- Siponimod is used as a (2E)-2- butenedioate (2:1 mixture), is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and is available as tablets in strengths of 0.25 mg, 1 mg, and 2 mg.
- the recommended maintenance dosage is 1 mg (in patients with a CYP2C9*1/*3 or *21* genotype) or 2 mg orally once daily.
- Ponesimod (also known as ACT-128800, PONVORY, (2Z,5Z)-5-[3-chloro-4-[(2R)-2,3- dihydroxypropoxy]benzylidene]-3-(2-methylphenyl)-2-(propylimino)-1 ,3-thiazolidin-4-one) is a selective modulator of the S1 Pi, S1 P 4 , and S1 P 5 receptor.
- Ponesimod is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and is available as tablets in strengths of 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, and 20 mg.
- the recommended maintenance dosage is 20 mg orally once daily.
- Cenerimod (also known as ACT-334441 , (S)-3- ⁇ 4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)- [1 ,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy ⁇ -propane-1 ,2-diol) is a selective S1 Pi receptor modulator.
- Cenerimod is developed for the treatment of systemic lupus erythematosus and was used in a clinical phase 2b study as tablets in strengths of 0.5 mg, 1 mg, 2 mg, and 4 mg.
- Etrasimod also known as APD334, 2-[(3R)-7-[[4-cyclopentyl-3-
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 52), wherein the S1 Pi receptor modulator is selected from ozanimod, siponimod, ponesimod, and cenerimod, or a pharmaceutically acceptable salt thereof.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 52), wherein the S1 Pi receptor modulator is cenerimod.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 55), wherein cenerimod is comprised in a pharmaceutical dosage form for oral administration (especially in a tablet formulation, notably in a film coated tablet).
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 55) or 56), wherein cenerimod is comprised in the pharmaceutical dosage form in a unit dose of 4 mg (especially 4.0 mg).
- unit dose refers to the amount of an active pharmaceutical ingredient (especially cenerimod) that is administered and/or is to be administered to a subject in a single dose.
- a unit dose is the amount of an active pharmaceutical ingredient (especially cenerimod) in a tablet or capsule (especially a tablet) for oral administration in case a single tablet or capsule is administered and/or is to be administered to the subject per administration.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 55) to 57), wherein cenerimod is to be administered and/or is administered to a patient once per day (once daily).
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 55) to 58), wherein cenerimod is to be administered and/or is administered to a subject for a treatment period of at least 6 months (especially at least 12 months, and notably at least 60 months).
- treatment period refers to the period between the first day of a treatment and the last day of an uninterrupted treatment with an active pharmaceutical ingredient (especially in relation to cenerimod), a pharmaceutical composition and/or a medicament, wherein a treatment is “uninterrupted” if it is in accordance with a regularly repeating dosing scheme such as, for example, once daily. For instance, if cenerimod is administered and/or is to be administered once daily for a treatment period of 6 months, this means that cenerimod is administered and/or is to be administered once at every day of the 6 months period.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 55) to 59), wherein cenerimod is to be administered and/or is administered to a subject chronically.
- chronical treatment refers to a treatment period starting with the first day of treatment with the respective active pharmaceutical ingredient (especially cenerimod) and ending on the day on which a further continuation of the treatment of the subject with the active pharmaceutical ingredient is no longer feasible or indicated.
- the treatment of the subject with the active pharmaceutical ingredient might be for instance no longer feasible or indicated for reasons such as side effects of the treatment, changes of the health condition of the subject (requiring for instance a different medication), changes of other relevant circumstances in the life of a subject, death of the subject and the like.
- chronical treatment refers to a treatment period of at least 10 years, starting with the first day of treatment with the respective active pharmaceutical ingredient (especially cenerimod) until a further continuation of the treatment of the subject with the active pharmaceutical ingredient is not feasible or indicated.
- treatment onset refers to the first day of treatment with the respective active pharmaceutical ingredient (especially the S1 Pi receptor modulator; and notably cenerimod).
- type 1 interferon mediated disease means a disease that is linked or related to and/or has a common cause with (especially that is linked to and/or has a common cause with) a high type 1 interferon (IFN-1) gene signature score in at least some of the subjects suffering from the disease.
- IFN-1 type 1 interferon
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 60), wherein the type 1 interferon mediated disease is selected from the group consisting of systemic lupus erythematosus, discoid lupus, lupus nephritis, glomerulonephritis, type I diabetes, inflammatory bowel disease (including Crohn’s disease, ulcerative colitis, and Celiac’s disease), multiple sclerosis, autoimmune thyroiditis, scleroderma, psoriasis, primary Sjogren’s disease, systemic sclerosis, rheumatoid arthritis, transplant rejection, dermatomyositis, polymyositis, idiopathic inflammatory myositis, sarcoidosis, Aicardi- Goutieres syndrome, vasculitis, Sting associated vasculopathy with onset in infancy (
- the S1 Pi receptor modulator (especially cenerimod) may be administered for the treatment of a type 1 interferon mediated disease or prophylactically in order to reduce the risk of developing a type 1 interferon mediated disease and/or to delay the onset of the symptoms.
- treat or “treatment” or “treating” used with reference to a disease means either that said disease is cured in the subject; or that, although the subject remains affected by the disease, part or all of the symptoms of said disease are either reduced or eliminated.
- prevent or “prevention” or “preventing” (or alternatively “prophylaxis” or “prophylactical(ly)”) used with reference to a disease means that the risk of developing said disease in the subject is reduced and/or that the onset of one or more symptoms of said disease in the subject is delayed.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 60), wherein the type 1 interferon mediated disease is systemic lupus erythematosus and/or lupus nephritis.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 60), wherein the type 1 interferon mediated disease is systemic lupus erythematosus.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 60), wherein the type 1 interferon mediated disease is lupus nephritis, cutaneous lupus, or lupus with central nervous system (CNS) manifestations.
- CNS central nervous system
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) is reached after 12 months treatment of the subject (especially of a subject having SLE) with the S1 Pi receptor modulator (especially cenerimod).
- mSLEDAI-2K modified systemic lupus erythematosus disease activity index 2000
- the mSLEDAI-2K score is based on the SLEDAI-2K (Gladman DD, et al. J Rheumatol 2002; 29(2) 288-291), modified to exclude leukopenia (Hermann V, et al. Lupus Science & Medicine 2019;6:e000354. doi:10.1136/lupus-2019-000354; ClinicalTrials.gov Identifier: NCT03742037).
- baseline refers to the value, score, index, or the like as measured, calculated or otherwise determined before (especially closely before and notably immediately before) treatment onset with the active pharmaceutical ingredient (such as the S1 Pi receptor modulator or cenerimod).
- active pharmaceutical ingredient such as the S1 Pi receptor modulator or cenerimod.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) of at least 2 points is reached after 12 months treatment of the subject (especially of a subject having SLE) with the S1 Pi receptor modulator (especially cenerimod).
- mSLEDAI-2K modified systemic lupus erythematosus disease activity index 2000
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) of at least 4 points is reached after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially cenerimod) in at least 30% of the subjects.
- mSLEDAI-2K modified systemic lupus erythematosus disease activity index 2000
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 67), wherein the reduction from baseline in mSLEDAI-2K is reached in at least 50% of the subjects.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 67), wherein the reduction from baseline in mSLEDAI-2K is reached in at least 70% of the subjects.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 1 point lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
- mSLEDAI-2K modified systemic lupus erythematosus disease activity index 2000
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 1.5 points lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
- mSLEDAI-2K modified systemic lupus erythematosus disease activity index 2000
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 2 points lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
- mSLEDAI-2K modified systemic lupus erythematosus disease activity index 2000
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 72), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially with cenerimod) is reached in at least 30 % of the subjects.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 72), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially with cenerimod) is reached in at least 50 % of the subjects.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 72), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially with cenerimod) is reached in at least 70 % of the subjects.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 72), wherein the probability of a response on SRI-4 after 12 months treatment of a subject (especially of a subject having SLE) is higher (especially statistically significant higher) in a subject treated with the S1 Pi receptor modulator (especially with cenerimod) than in a subject treated with placebo.
- a response on SLE responder index (SRI)-4 is defined as: reduction of at least 4 points in the mSLEDAI-2K compared to baseline; and no new BILAG A organ domain score and not more than one new BILAG B organ domain score compared to baseline; and no worsening from baseline in subjects’ lupus disease activity, where worsening is defined by an increase >0.30 points on a 3-point Physician’s Global Assessment (PGA) visual analogue scale (VAS).
- PGA Global Assessment
- VAS visual analogue scale
- the BILAG (British Isles Lupus Assessment Group) score is defined in Romero-Diaz J et al Arthritis Care Res (Hoboken). 2011 Nov; 63 Suppl 11 (0 11):S37-46. doi: 10.1002/acr.20572.
- PGA Global Assessment
- VAS visual analog scale
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 76), wherein the time to first confirmation of a 4-month sustained mSLEDAI-2K response (defined as a reduction of at least 4 points from baseline) is shorter (especially statistically significant shorter) in subject(s) treated with the S1 Pi receptor modulator (especially with cenerimod) than in subject(s) treated with placebo.
- a further embodiment of the invention relates to cenerimod, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 76), wherein the time from treatment onset with cenerimod to first confirmation of a 4-month sustained mSLEDAI-2K response (defined as a reduction of at least 4 points from baseline) is statistically significant shorter in subject(s) treated with cenerimod than in subject(s) treated with placebo.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 76), wherein the time to first confirmation of a 4-month sustained response in mucocutaneous manifestations is shorter (especially statistically significant shorter) in subject(s) treated with the S1 Pi receptor modulator (especially with cenerimod) than in subject(s) treated with placebo.
- the time to first confirmation of a 4-month sustained response in mucocutaneous manifestations is defined as: - no increase in overall mSLEDAI-2K score;
- a further embodiment of the invention relates to cenerimod, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 76), wherein the time from treatment onset with cenerimod to first confirmation of a 4-month sustained response in mucocutaneous manifestations is statistically significant shorter in subject(s) treated with cenerimod than in subject(s) treated with placebo.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 80), wherein the S1 Pi receptor modulator is cenerimod, or a pharmaceutically acceptable salt thereof, and wherein a clinically proven effective amount of cenerimod is administered and/or is to be administered to the subject.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human (especially a human patient).
- subject includes any human or nonhuman animal.
- Nonhuman animal includes all vertebrates.
- subject refers to a human, and especially to a human patient.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from a type 1 interferon mediated disease.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from systemic lupus erythematosus and/or lupus nephritis.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from systemic lupus erythematosus.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from systemic lupus erythematosus, and wherein the subject has a mSLEDAI-2K score > 6 and a clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
- the clinical mSLEDAI-2K is the mSLEDAI-2K assessment score without the inclusion of points attributable to hematuria, proteinuria, pyuria, low complement, increased DNA binding, and thrombocytopenia.
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from systemic lupus erythematosus, and wherein the subject has (i) a mSLEDAI-2K score > 6 and a clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers); (ii) a British Isles Lupus Assessment Group-2004 (BILAG) Grade B in > 2 organ systems or a BILAG Grade A in > 1 organ system; and (iii) Physician's Global Assessment (PGA) score > 1.0 on a 0 to 3 VAS.
- BILAG British Isles Lupus Assessment Group-2004
- PGA Physician's Global Assessment
- a further embodiment of the invention relates to a S1 Pi receptor modulator (especially cenerimod), or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 87), wherein the subject is a subject receiving standard background therapy (wherein it is understood that such standard background therapy is suitable for the treatment of a type 1 interferon mediated disease, especially of systemic lupus erythematosus).
- Standard background therapy for the treatment of systemic lupus erythematosus may be an antimalarial, such as hydroxychloroquine, chloroquine, or quinacrine; mycophenolate mofetil or mycophenolic acid; azathioprine; methotrexate; an oral corticosteroid, such as prednisone, prednisolone, hydrocortisone, methylprednisolone, or dexamethasone; belimumab; anifrolumab; or any other drug approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or a corresponding national regulatory agency and/or used as standard of care at the date of treatment onset with the S1 Pi receptor modulator.
- FDA U.S. Food and Drug Administration
- EMA European Medicines Agency
- Cenerimod can be used as medicament according to this invention, e.g. in the form of pharmaceutical compositions especially for enteral, or for parenteral administration.
- Dosage forms suitable for enteral administration may be tablets or capsules (especially tablets) comprising a pharmaceutical composition comprising an efficacious amount of cenerimod, or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition comprising cenerimod in a pharmaceutically effective amount may additionally comprise further conventional excipients and/or additives, which may be used alone or in combination.
- any reference to a S1 Pi receptor modulator in this specification is to be understood as referring also to the pharmaceutically acceptable salts of such a S1 Pi receptor modulator.
- cenerimod refers to cenerimod or a pharmaceutically acceptable salt form of cenerimod, preferably to cenerimod in free base form.
- salts refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects.
- Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound.
- “Handbook of Pharmaceutical Salts. Properties, Selection and Use.’ P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008 and ‘Pharmaceutical Salts and Cocrystals’, Johan Wouters and Luc Quere (Eds.), RSC Publishing, 2012.
- the term “about” placed before a numerical value “X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X.
- the term “about” placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C.
- any embodiment relating to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease also relates to the use of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment (especially treatment) of a type 1 interferon mediated disease; and to a method of prevention/prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease, the method comprising administering to a subject in need thereof an effective amount (especially a pharmaceutically effective amount) of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof.
- any embodiment relating to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease also relates to the use of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease; and to a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease, the method comprising administering to a subject in need thereof an effective amount (especially a pharmaceutically effective amount) of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof.
- a further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease, the method comprising administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject has a high type 1 interferon (IFN-1) gene signature score.
- a S1 Pi receptor modulator or a pharmaceutically acceptable salt thereof
- type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44, and IFI44L; or e) IFI6, RSAD2, IFI44L,
- type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 ,
- type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
- type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
- the type 1 interferon gene signature score of the subject is at least 0.5 units, at least 1 unit, at least 2 units or at least 3 units (especially at least 1 unit) above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
- the threshold value is an IFN-1 gene signature score value that is selected from values between 1.8 to 4.0 (i.e. 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0; especially 2.0 to 3.0, and notably 2.0 to 2.5) standard deviations above the arithmetic mean of the IFN-1 gene signature score values from at least 20, at least 50, at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
- the threshold value of the IFN-1 gene signature score is 2 standard deviations above the arithmetic mean value from at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
- RNA gene expression levels of the type 1 interferon-associated genes (especially of RSAD2, IFI44, IFI44L, and IFI27; or of RSAD2, IFI27, IFIT1 , and HERC5; and notably of RSAD2, IFI27, IFIT1 , and HERC5) in a blood sample of a subject (notably by measuring respective peak height by capillary electrophoresis);
- Formula (I) and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the type 1 interferon-associated genes.
- RNA gene expression levels of the type 1 interferon-associated genes (especially of RSAD2, IFI44, IFI44L, and IFI27; or of RSAD2, IFI27, IFIT1 , and HERC5; and notably of RSAD2, IFI27, IFIT1 , and HERC5) in a blood sample of a subject (notably by measuring respective peak height by capillary electrophoresis);
- Formula (I) and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the four type 1 interferon-associated genes.
- a further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising: a) providing a biological sample (especially a blood sample or a serum sample, and notably a blood sample) from the subject; b) assaying gene expression of at least three (especially at least four) type 1 interferon- associated genes selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6 (especially I
- the normalized expression values are determined by (i) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject; (ii) calculating the binary logarithm (log 2 ) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof; and (iii) calculating the normalized expression value for each of the type 1 interferon-associated genes according to Formula (II)
- the type 1 interferon gene signature score of the subject is at least 0.5 units, at least 1 unit, at least 2 units or at least 3 units (especially at least 1 unit) above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
- the threshold value is an IFN-1 gene signature score value that is selected from values between 1.8 to 4.0 (i.e. 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0; especially 2.0 to 3.0, and notably 2.0 to 2.5) standard deviations above the arithmetic mean of the IFN-1 gene signature score values from at least 20, at least 50, at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
- the threshold value of the IFN-1 gene signature score is 2 standard deviations above the arithmetic mean value from at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans. 123) The method according to any one of embodiments 107) to 118), wherein the threshold value of the IFN-1 gene signature score is selected from values between -1.0 and 0 (especially about -0.5, and notably -0.5).
- a further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising: a) providing a biological sample (especially a blood sample or a serum sample, and notably a blood sample) from the subject; b) assaying gene expression of the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5 in the biological sample (especially by measuring peak height in capillary electrophoresis electropherograms); c) determining a normalised expression value of each assayed gene by (i) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in the biological sample of the subject; (ii) calculating the binary logarithm (log 2 ) of the expression levels of each of the three housekeeping genes
- a further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein at least three (especially at least four) type 1 interferon- associated genes are upregulated in the subject (especially in a biological sample from the subject), wherein the type 1 interferon-associated genes are selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1
- a further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein the concentration/level of interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is elevated compared to a healthy subject.
- IFN-y interferon-gamma
- a further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein the subject has a concentration/level (especially a concentration/level in blood plasma) of interferon-gamma (IFN-y) above 9.5 pg/mL.
- a concentration/level especially a concentration/level in blood plasma
- a further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-gamma (IFN-y) in the biological sample; and c) administering a pharmaceutically effective amount of a S1Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof when the concentration/level of interferon-gamma (IFN-y) is elevated compared to the concentration/level of interferon-gamma (IFN-y) in a biological sample from a healthy subject and/or is above 9.5 pg/mL.
- a biological sample especially a plasma sample
- IFN-y concentration/level of interferon-gamma
- the method further comprises: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the biological sample; and c) administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof when in addition to the other condition the concentration/level of interferon-alpha (IFN-a ) and/or of interferon- gamma (IFN-y) is elevated compared to the concentration/level in a biological sample from a healthy subject.
- a biological sample especially a plasma sample
- IFN-y interferon-gamma
- the method further comprises: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the biological sample; and c) administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof when in addition to the other condition the concentration/level of interferon-alpha (IFN-a ) is above 0.1 pg/mL and/or when the concentration/level of interferon-gamma (IFN-y) is above 9.5 pg/mL.
- a biological sample especially a plasma sample
- IFN-y interferon-gamma
- the S1 Pi receptor modulator is selected from fingolimod, ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof (especially from ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof, and notably from ozanimod, siponimod, ponesimod, cenerimod, or a pharmaceutically acceptable salt thereof).
- S1 Pi receptor modulator is selected from ozanimod, siponimod, ponesimod, and cenerimod, or a pharmaceutically acceptable salt thereof.
- cenerimod is comprised in a pharmaceutical dosage form for oral administration (especially in a tablet formulation, notably in a film coated tablet).
- cenerimod is comprised in the pharmaceutical dosage form in a unit dose of 4 mg (especially 4.0 mg).
- cenerimod is to be administered and/or is administered to a patient once per day (once daily).
- cenerimod is to be administered and/or is administered to a subject for a treatment period of at least 6 months (especially at least 12 months, and notably at least 60 months).
- a further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 143) to 147), wherein cenerimod is to be administered and/or is administered to a subject chronically.
- the type 1 interferon mediated disease is selected from the group consisting of systemic lupus erythematosus, discoid lupus, lupus nephritis, glomerulonephritis, type I diabetes, inflammatory bowel disease (including Crohn’s disease, ulcerative colitis, and Celiac’s disease), multiple sclerosis, autoimmune thyroiditis, scleroderma, psoriasis, primary Sjogren’s disease, systemic sclerosis, rheumatoid arthritis, transplant rejection, dermatomyositis, polymyositis, idiopathic inflammatory myositis, sarcoidosis, Aicardi- Goutieres syndrome, vasculitis, Sting associated vasculopathy with onset in infancy (SAVI) or chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature
- SAVI Sting associated vasculopathy with onset in infancy
- a further embodiment of the invention relates to a method of treating a type 1 interferon mediated disease (especially systemic lupus erythematosus) in a subject in need thereof, wherein the subject has a high type 1 interferon (IFN-1) gene signature score; the method comprising administering to the subject a pharmaceutical composition comprising a clinically proven effective amount of a S1 Pi receptor modulator (especially cenerimod), or a pharmaceutically acceptable salt thereof.
- a type 1 interferon mediated disease especially systemic lupus erythematosus
- IFN-1 type 1 interferon
- Efficacy can be measured based on change in the course of the disease in response to an agent of the present invention.
- a S1Pi receptor modulator especially cenerimod
- cenerimod is administered to a subject in an amount and for a time sufficient to induce an improvement, preferably a sustained improvement, in at least one indicator that reflects the severity of the disorder that is being treated.
- Various indicators that reflect the extent of the subject's illness, disease or condition can be assessed for determining whether the amount and time of the treatment is sufficient.
- Such indicators include, for example, clinically recognized indicators of disease severity, symptoms, or manifestations of the disorder in question.
- the degree of improvement generally is determined by a physician, who can make this determination based on signs, symptoms, biopsies, or other test results, and who can also employ questionnaires that are administered to the subject, such as quality-of-life or patient-reported outcome questionnaires developed for a given disease.
- a compound of the present invention can be administered to achieve an improvement in a subject's condition related to systemic lupus erythematosus. Improvement can be indicated by an improvement in an index of disease activity, by amelioration of clinical symptoms or by any other measure of disease activity.
- such measure of disease activity is the modified systemic lupus erythematosus disease activity index 2000 as compared to baseline and/or as compared to placebo.
- such measure of disease is the Systemic Lupus Erythematosus Responder Index (SRI-4) as compared to baseline and/or as compared to placebo.
- SRI-4 Systemic Lupus Erythematosus Responder Index
- such measure of disease is the time to first confirmation of a 4-month sustained mSLEDAI-2K response (defined as a reduction of at least 4 points from baseline) as compared to placebo.
- such measure of disease is the time to first confirmation of a 4-month sustained response in mucocutaneous manifestations as compared to placebo.
- a clinically proven effective amount of cenerimod is an amount that results in a reduction in the modified systemic lupus erythematosus disease activity index 2000 as compared to baseline and/or as compared to placebo; as demonstrated via clinical trial having the protocol as described in the “Opus Study Overview” herein below.
- AEs treatment- emergent adverse events
- TEAEs treatment- emergent adverse events
- “adverse event”, “treatment-emergent adverse event”, and “adverse reaction” mean any harm, unfavorable, unintended, or undesired sign or outcome associated with or caused by administration of a pharmaceutical composition or therapeutic. It is an untoward medical occurrence in a subject administered a medicinal product.
- VAS Visual analogue scale
- cenerimod reduces both the IFN-1 gene signature score and IFN-oc protein in the plasma of patients treated with cenerimod (Figure 3A) both of which are more abundant in patients with SLE compared to healthy volunteers (figure 3B). Patients with high IFN-oc protein levels at baseline display a larger reduction in the mSLEDAI-2K score as compared to the IFN alpha protein low cohort (figure 3C).
- cenerimod 4 mg reduces IFN gamma protein in plasma at 6 months compared to baseline and compared to placebo (Figure 4A), which also is more abundant in patients with SLE compared to healthy volunteers (figure 4B). Patients with high IFN gamma protein levels at baseline display a larger reduction in the mSLEDAI-2K score as compared to the IFN gamma protein low cohort (figure 4C).
- a modulation of biological activity is reflected in changes of gene expression. These changes can be described by specific gene expression signatures.
- a gene signature is defined by a set of genes that show increased or decreased expression upon the biological activity. Gene signatures are most often analyzed using quantitative reverse transcription PCR (RT-qPCR), which allows standardized expression levels for each gene of interest to be derived.
- RT-qPCR quantitative reverse transcription PCR
- the IFN-1 signature reflects IFN-regulated genes, meaning that those genes are upregulated due to the biological activity of type 1 IFNs.
- An IFN-1 gene signature was first described in 2003 in cells isolated from patients with SLE [Baechler, EC. et al., PNAS 2003, 100(5), 2610-2615, PMID:12604793],
- IFN-1 gene signature An important property of the IFN-1 gene signature is the bimodal distribution in patients with SLE allowing separation into high or low IFN-1 gene signature strata [El-Sherbiny, YM. et al., Scientific Reports 2018, 8, 5793, DOI :10.1038/s41598-018-24198-1 , PMID: 29643425],
- There are two most used IFN-1 gene signatures in clinical studies (AstraZeneca [AZ] and DxTerity signature). Although both signatures comprise 4 genes, the difference is in the selection of genes.
- Both signatures contain IFI27 and RSAD2, but AZ includes in addition IFI44 and IFI44L, whereas DxTerity uses IFIT1 and HERC5.
- the two IFN-1 gene signatures correlate very well and will therefore classify the SLE patients in the same high and low strata as long as the cut-off is derived in the same way. It was previously shown different IFN-1 gene signatures will classify patients into the same IFN-1 status (Abedi M, Comparison Of Different Type 1 IFN Signatures Demonstrates Concordance In A Real World, Home Monitored Systemic Lupus Erythematosus Cohort, EULAR 2018, poster #SAT0041).
- the DxTerity gene expression assay contains ten interferon genes (EIF2AK2, HERC5, IFI27, IFI44, IFI44L, IFI6, IFIT1 , ISG15, MX1 , RSAD2). Four of those genes (HERC5, IFIT1 , IFI27, and RSAD2) are used in the IFN-1 test to define the IFN-1 gene signature status (high/low).
- the assay is using a proprietary Chemical Ligation-dependent Probe Amplification (CLPA/DxDirect) technology.
- the DxTerity signature cut-off point of -0.5 (for differentiating IFN high and low subjects) is based on the 95th percentile of more than 500 healthy human ( Figure 1A), while the AZ cut-off point would lead to more than 10% of healthy subjects being classified as high.
- Each target gene expression level is normalized to three housekeeping (normalizer) genes (ACTB, GAPDH, and TFRC).
- the gene expression level of each individual subject is calculated from the capillary electrophoresis electropherogram using the intensity of the fragment peak height (RFU) corresponding to the 4 interferon responsive genes relative to the average of the intensities of three normalizer gene peak heights (from the same subject) using the following formula:
- the IFN-1 gene signature score of the subject is determined by averaging the normalized expression values of the HERC5, IFI27, IFIT1 , and RSAD2 genes.
- the high/low cut-off (-0.5) is based on the 95th percentile of more than 500 healthy human and is placed 2 standard deviations above the mean IFN-1 gene signature score of the healthy volunteers, and it falls in the trough of the classic bimodal IFN-1 gene signature score distribution seen for SLE patients.
- the study design was a double-blind randomized placebo-controlled study in patients with SLE. A total of 85 patients were included in the 4mg cenerimod arm and 86 patients in the placebo arm.
- the primary objective of the study was to assess the efficacy of 6 months of cenerimod at 4 mg in subjects with moderate to severe SLE. Secondary and exploratory objectives (6 months) included, but not limited, were to the effect on SLE biomarkers and exploratory biomarkers, to assess safety and tolerability of cenerimod doses, to assess the effect on quality of life and fatigue using patient reported outcome (PRO) instrument and to assess the effect on SLE biomarkers.
- the inclusion criteria were as follows: A Diagnosis of SLE made at least 6 months prior to Screening (at least 4 ACR criteria), a modified SLEDAI-2K (mSLEDAI-2K) score > 6 of at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers) at screening.
- the modified SLEDAI-2K is defined as SLEDAI-2K with the removal of leukopenia which is one of the scores utilized in the SLEDAI-2K composite score. SLEDAI-2K is described elsewhere (Gladman et al, J Rheumatol. 2002 Feb;29(2):288-91).
- a clinical mSLEDAI-2K score > 4 at randomization was required. Further, a positive Antinuclear Antibody test (ANA) with titre >1 :80 (by immunofluorescence assay) AND/OR positive anti-dsDNA with titre >30 lU/mL at randomization was required. Participants had to be on a stable background SLE medication for a period of at least 30 days (15 days for corticosteroids) prior to randomization. Participants if using Corticosteroids had to have ⁇ 40 mg/day prednisone or equivalent. Women of childbearing potential (WOCBP) must have agreed to use highly effective methods of contraception.
- WOCBP Women of childbearing potential
- the exclusion criteria were the following: Patients having active lupus nephritis (defined by proteinuria > 1 .5 g/24 h, or equivalent using spot urine protein-to-creatinine ratio) or a renal biopsy demonstrating immune complex-mediated glomerulonephritis compatible with lupus nephritis.
- Patients exhibiting CNS lupus e.g., aseptic meningitis, seizures, cerebritis, polyneuropathy, cerebrovascular disease, organic brain syndrome
- severe forms of vasculitis requiring systemic immunosuppressive treatment e.g., retinal vasculitis, coronary vasculitis, pulmonary vasculitis, mesenteric vasculitis
- the Study treatment was the following: A daily tablet of cenerimod or placebo was taken orally irrespective of food intake and preferably in the morning.
- NSAIDs Aspirin (acetylsalicylic acid), Ibuprofen, Naproxen, Celecoxib, Other NSAIDs, Prednisone or equivalent ⁇ 40 mg/day, anti-malaria’s: Hydroxychloroquine, Chloroquine, Quinacrine, Mycophenolate mofetil, Mycophenolic acid, Azathioprine, Methotrexate, Belimumab must have started at least 30 days prior to Screening.
- OCS Oral Corticosteroids
- the primary efficacy endpoint is the change from baseline to Month 6 in the modified SLEDAI-2K score. Further secondary endpoints were:
- the Physician Global Assessment is a visual analog scale (VAS) using 3 benchmarks for assessing disease activity over the last 2 weeks (Luijten KMAC et al, Autoimmunity Reviews Volume 11 , Issue 5, March 2012, Pages 326-329). Mild flare will score 1.0 point, moderate flares will score a 2.0-2.5 point and severe flares will score a 3 on the 0-3 analog scale.
- Opus studies are two phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects (18 years to 75 years) with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy.
- Subjects are randomized 1 :1 to either cenerimod or matching placebo.
- Cenerimod is supplied once daily in addition to background SLE therapy as film-coated tablets at the dose of 4 mg.
- This endpoint is based on the SLEDAI-2K index, modified to exclude leukopenia. All values of mSLEDAI-2K from baseline through Month 12 visits are accounted for in the assessment of this endpoint.
- SRI-4 Systemic Lupus Erythematosus Responder Index
- SRI-4 Response on SRI-4 is defined as: o Reduction from baseline of at least 4 points in the mSLEDAI-2K, and o No new British Isles Lupus Assessment Group-2004 (BILAG) A organ domain score and not more than one new BILAG B organ domain score compared to baseline, and o No worsening from baseline in subjects' lupus disease activity, where worsening is defined as an increase > 0.30 points on a 3-point Physician's Global Assessment visual analog scale, and o No violation of protocol-specified medication rules detailed in the core protocol.
- BILAG British Isles Lupus Assessment Group-2004
- a response is defined as a reduction of at least 4 points from baseline.
- Time to first confirmation of a 4-month sustained response in mucocutaneous manifestations (Time Frame: Day 1 (pre-dose baseline) to Month 12).
- mSLEDAI-2K Response is defined as: o No increase in the overall mSLEDAI-2K score, and o Remission (score of zero) from baseline in the mSLEDAI-2K score of mucocutaneous manifestations.
- ICF Signed Informed Consent Form
- mSLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index-2000
- clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
- the mSLEDAI-2K score does not include “leukopenia”.
- BILAG British Isles Lupus Assessment Group-2004
- PGA Physician's Global Assessment
- VAS Visual Analogue Scale
- o Anti-malarials ⁇ 400 mg/day hydroxychloroquine, ⁇ 500 mg/day chloroquine, ⁇ 100 mg/day quinacrine.
- Mycophenolate mofetil ⁇ 2 g/day
- mycophenolic acid ⁇ 1 .44 g/day
- o Azathioprine ⁇ 2 mg/kg/day
- o Methotrexate ⁇ 25 mg/week.
- OCS Oral Corticosteroids
- OCS OCS is the only SLE background medication: > 7.5 mg/day and ⁇ 30 mg/day prednisone or equivalent.
- OCS OCS is not the only SLE background medication: ⁇ 30 mg/day prednisone or equivalent.
- o Belimumab ⁇ 10 mg/kg every 4 weeks intravenously, or 200 mg/week subcutaneously (s.c.).
- Treatment with antimalarials, mycophenolate mofetil, mycophenolic acid, azathioprine, methotrexate or belimumab must have been started at least 90 days prior to Screening. Treatment with OCS must have been started at least 30 days prior to Screening.
- BILAG British Isles Lupus Assessment Group-2004
- Presence of at least one of the following items of serological evidence of active SLE or biological variables predictive of Type 1 Interferon (IFN-1) high signature in a Screening sample as measured by central laboratory: o Anti-dsDNA antibodies elevated to above normal. o Complement C3 ⁇ lower limit of normal. o Antinuclear Antibodies with a titer of at least 1 : 160. o Anti-Smith antibody elevated to above normal. o Platelets ⁇ 200 000/pL. o Urine protein/creatinine ratio > 12.5 mg/mmol (110.5 mg/g).
- OCS OCS is the only SLE background medication: > 7.5 mg/day and ⁇ 30 mg/day prednisone or equivalent.
- OCS OCS is not the only SLE background medication: ⁇ 30 mg/day prednisone or equivalent).
- o Belimumab ⁇ 10 mg/kg every 4 weeks intravenous (i.v.) or ⁇ 200 mg/week s.c.).
- - Severe central nervous system lupus or active severe or unstable neuropsychiatric SLE characterized by: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; or mononeuritis multiplex: o That would make the subject unable to fully understand the ICF; OR o Where, in the opinion of the Principal Investigator, protocol-specified standard of care is insufficient and the use of a more aggressive therapeutic approach, such as adding i.v. cyclophosphamide and/or high dose i.v. pulse corticosteroid (CS) therapy or other treatments not permitted in the protocol is indicated.
- CS pulse corticosteroid
- OCT optical coherence tomography
- o lymphocyte count ⁇ 500 /pL (0.5 x 10 A 9/L) ; o hemoglobin ⁇ 7 g/dL; o white blood cell count ⁇ 2000/pL (2.0 x 10 A 9/L); or o platelets ⁇ 25000/pL (25 x 10 A 9/L) at screening assessment.
- B cell-depleting biological agents e.g., rituximab or ocrelizumab
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a S1P1 receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a type 1 interferon mediated disease in a subject that has a high type 1 interferon (IFN-1) gene signature score or elevated levels of interferon-alpha (IFN-α) and/or interferon-gamma (IFN-γ) in 5 blood plasma.
Description
S1Pi receptor modulators for use in the treatment of type 1 IFN mediated diseases
Field of the invention
The present invention relates to a S1Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a type 1 interferon mediated disease in a subject that has a high type 1 interferon (IFN-1) gene signature score or elevated levels of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in blood plasma.
Backaround of the invention
Sphingosine 1 -phosphate (S1 P) is a lipid mediator formed by the metabolism of sphingomyelin. In vertebrates, S1 P is secreted into the extracellular environment and signals via G protein coupled S1 P receptors including the S1 P1 receptor which plays an important role in lymphocyte trafficking [Mendelson, K. et al., Development 2014, 141 , 5-9, PMID:24346695],
S1 P1 receptor modulators are approved for the treatment of multiple sclerosis and Inflammatory Bowel Disease and are being investigated in further inflammatory diseases involving lymphocyte driven inflammatory processes [Burg, N. et al., Nat Rev Rheumatol. 2022, 18(6), 335-351 , PMID:35508810],
(S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1 ,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl- phenoxy}-propane-1 ,2-diol (hereinafter also referred to as “COMPOUND” or “cenerimod”) is a potent, selective, and orally active S1 P1 receptor modulator which prevents the egress of lymphocytes from secondary lymphoid organs into the vascular circulation, via internalization of the S1 P1 receptor. As such, its immunomodulatory role in autoimmune diseases may be of benefit in treating such diseases in which lymphocytes play an important role in propagating disease. The preparation of (S)-3-{4-[5-(2-cyclopentyl-6- methoxy-pyridin-4-yl)-[1 ,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1 ,2-diol and the medicinal uses thereof are described in PCT applications WO 2011/007324, WO 2013/175397 and WO 2016/184939.
Both B and T lymphocytes have been implicated in playing a major role in the pathogenesis of systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease of unknown etiology, characterized by the production of high titers of pathogenic
autoantibodies, infiltrating lymphocytes, and tissue damage across multiple organ systems [Rahman, A. et al., N Engl J Med 2008, 358, 929-939, PMID: 18305268],
In a phase 2 clinical trial cenerimod reduced both B and T lymphocytes in the circulation confirming the mode of action (Hermann V, et al. Lupus Science & Medicine 2019;6:e000354. doi:10.1136/lupus-2019-000354). Furthermore, cenerimod reduced interferon (IFN)-associated proteins in plasma [Strasser, DS et al., RMD Open 2020, 6, e001261 , PMID: 32917831],
IFNs are central effector molecules produced in large amounts during an immune response to infection, activating defense mechanisms and resulting in the inhibition of microbial replication. Type 1 IFNs are the largest group and comprise several classes and subclasses. Almost all cells can produce IFN-a and I FN-|3, members of the Type 1 IFNs, including dendritic-, monocytic- T and B cells of the immune system. IFN-x is the only type 2 IFN and is mainly produced by NK cells and T cells of the immune system [McNab, F. et al., Nat Rev Immunol 2015, 15, 87-103, PMID:25614319; Rbnnblom, L. et al., Lupus Sci Med 2019, 6, e000270, PMID:31497305; Colonna, M. et al., Current Opinion Immunol 2002, 14, 373-379, PMID:11973137],
Type-1 IFNs signal through a heterodimeric transmembrane receptor composed of the subunits IFNAR1 and IFNAR2, broadly expressed across multiple cell types. Similarly, type 2 IFN engage with the heterodimer IFNGR1 and IFNGR2. Both IFNAR and IFNGR complexes recruit JAK kinase family members. IFNAR recruits TYK2 and JAK1 while IFNGR recruits JAK1 and JAK2. This leads to subsequent STAT1 and STAT2 phosphorylation and the subsequent translocation of the signaling pathway transcription factors into the nucleus. These in turn bind to IFN response elements on the DNA, initiating the transcription of a whole host of genes [Platanias, LC., Nat Rev Immunol 2005, 5, 375- 386, PMID:15864272],
Importantly, the activation of these pathways is to a certain degree overlapping. The activation of the gene transcription by IFNs can be described with an IFN gene signature, can consist of many hundreds of genes, is dependent on the kinetics and cell types involved, and can lead to a multitude of outcomes and nuances [Rbnnblom, L. et al., Curr Opin Rheumatol 2013, 25(2), 248-253, PMID:23249830],
The observation that IFNs are elevated in SLE was already made in the late 1970s and an indication that IFNs may in fact cause SLE-like symptoms comes from studies of interferonopathies where a constitutive overproduction of Type 1 IFNs caused by genetic mutations in genes within both the type 1 and type 2 IFN inducing pathway have been found. These individuals have a prominent IFN signature, and some patients present an
SLE like-phenotype [Lee-Kirsch, MA., Annu Rev Med 2017, 68, 297-315, PMID:27813875], The reasons for elevated IFN levels in SLE are not clearly understood and not all patients diagnosed with SLE have an elevated type 1 IFN [Northcott, M. et al., Lupus Sci Med 2022, 9, e000625, PMID:35197305], There are many lines of evidence suggesting genetic predisposition and environmental risk factors may lead to elevated levels of IFNs. Principally this reflects the involvement of multiple pattern recognition receptors in IFN activation mentioned above and their means of activation. A prominent mechanism is thought to be immune complexes which consist of autoantibodies, for example anti-dsDNA and anti-nuclear antibodies, nucleic acids, and nucleic acid binding proteins. This suggests nucleic acids as potential trigger and having autoantibodies against nucleic acids represents a risk factor to develop SLE.
Nucleic acids are sensed among other cells by plasmacytoid dendritic cells (pDCs), which are thought to be a key cell type producing type 1 IFNs in SLE.
Increased IFN signaling has not only been demonstrated in SLE but in other autoimmune diseases too, although the frequency and distribution within the population is unique to each autoimmune disease [Rbnnblom, L. et al., Curr Opin Rheumatol 2013, 25(2), 248- 253, PMID:23249830],
Although pDCs produce large amounts of IFN Type 1 [Celia, M. et al., Nature Med 1999, 5(8), 919-923, PMID:10426316], other cell types may be involved in IFN production in SLE including keratinocytes, endothelial cells, fibroblasts and monocytes, NK cells, B cells and T cells. Finally, genetic risk factors have been identified in SLE that are associated with IFN production or responses to IFNs further supporting the hypothesis that perturbations in IFN regulation may contribute to SLE [Deng, Y. et al., Curr Rheumatol Rep 2017, 19, 68 PMID:28983873, Catalina, MD. et al., Communications Biology 2019, 2(140), https://doi.Org/10.1038/S42003-019-0382-x, PMID:31044165],
Gene transcription analysis of IFN-induced genes was initially performed in 2003 utilizing peripheral blood from SLE patients which demonstrated that hundreds of genes associated with IFN activation were induced [Baechler, EC. et al., PNAS 2003, 100(5), 2610-2615, PMID:12604793] and provided evidence of an IFN gene signature in patients with SLE. Therefore, the IFN-1 signature reflects IFN-regulated genes, meaning that those genes are upregulated due to the biological activity of type 1 IFNs. Subsequent studies have demonstrated between 50 and 80% of SLE patients show a consistent presence of an IFN- 1 signature from the blood and this is stable over time [Northcott, M. et al., Lupus Sci Med 2022, 9, e000625, PMID:35197305; Kirou, KA. et al., Arthritis Rheumatism, 2004, 50(12), 3958-3967, PMID:15593221 ; Oke, V. et al., Arthritis Research Therapy 2019, 21 , 107,
PMID:31036046; Psarras, A. et al., Rheumatology 2017, 56, 1662-1675, PMID:28122959; Ronnblom, L. et al., Lupus Sci Med 2019, 6, e000270, PMID:31497305], The communality between all IFN-1 gene signatures lies in the fact that IFN response elements are present in the genes induced by IFN signaling.
An increase in IFN signaling has broad and wide-ranging effects on the body and increased IFN production may be linked to potential disease manifestations in patients with SLE, the principal ones are summarized below.
A prominent association is seen between elevated IFN and SLE associated nephritis [Feng, X. et al., Arthritis Rheumatism 2006, 54(9), 2951-2962, PMID:16947629; Kirou, KA. et al., Arthritis Rheumatism, 2005, 52(5), 1491-1503, PMID:15880830], Further, IFN has also been shown to be high in the kidney tissue suggesting a strong link of IFN with kidney damage [Castellano, G. et al., Arthritis Research Therapy 2015, 17, 72, PMID:25889472],
This evidence clearly suggests that IFNs participate in SLE disease, however the association of a blood IFN signature and clinical disease characteristics is not limited to any one manifestation. Further the IFN signature does not distinguish between high and low disease activity [Kennedy, WP. et al., Lupus Sci Med 2015, 2, e000080, PMID:25861459], as defined by various criteria, but can predict the subsequent disease severity over time [Mai, L. et al., Arthritis Research Therapy 2021 , 23, 29, PMID: 33451338],
Data on the distribution of type 1 IFN gene signature high vs IFN signature low within the general SLE population is somewhat limited but reports have placed it in the range of 60- 80% [Psarras, A. et al., Rheumatology 2017, 56, 1662-1675, PMID:28122959], An important property of the IFN-1 gene signature is the bimodal distribution in patients with SLE allowing separation into high or low IFN-1 gene signature strata [El-Sherbiny, YM. et al., Scientific Reports 2018, 8, 5793, DOI :10.1038/s41598-018-24198-1 , PMID: 29643425] and observed in a double-blind, randomized, placebo-controlled Phase 2b clinical study in patients with SLE (the CARE study; Figure 1A). In IFN-1 high populations reports have shown an association with renal aspects of disease, low complement C3 and autoantibodies, in keeping with the molecular function of IFNs [Landolt-Marticorena, C. et al., Ann Rheum Dis 2009, 68, 1440-1446, PMID:18772188; Feng, X. et al., Arthritis Rheumatism 2006, 54(9), 2951-2962, PMID:16947629; Kirou, KA. et al., Arthritis Rheumatism, 2005, 52(5), 1491-1503, PMID:15880830], In a longitudinal study, patients with a high type 1 interferon (IFN-1) gene signature score (“IFN-1 high patients”) were more likely to be receiving higher immunosuppressants and glucocorticoids than IFN-1 low patients (75% vs 50%), were likely to be younger and of Asian ancestry [Northcott, M. et al., Lupus Sci Med 2022, 9, e000625, PMID:35197305], The effect of Glucocorticoids on
IFN gene expressions was evaluated in a small cohort of SLE patients. The authors saw no effect of glucocorticoid dose on type 1 interferon -regulated gene expression. Patients with a high type 1 interferon gene signature had reduced glucocorticoid gene signature expression compared with patients with a low type 1 interferon gene signature matched for glucocorticoid dose, suggesting type 1 interferon inhibits glucocorticoid-stimulated gene expression [Northcott, M. et al., Lancet Rheumatology 2021 , 3(5), e357-e370, DOI: 10.1016/S2665-9913(21 )00006-0] .
The prominent role of IFNs in SLE has prompted efforts to target this pathway as a means of treating SLE and has been investigated in clinical trials. A prime example is anifrolumab, an antibody targeting the IFN-1 receptor. In addition, further potential therapies have been investigated for their potential ability to modulate IFN-1 gene signature score.
The phase 3 studies of anifrolumab confirmed the suppression of the interferon signature in patients with IFN-1 high at baseline seen in a phase 2 trial, although the association of this effect with clinical efficacy was not demonstrated. In TULIP 1 the efficacy of anifrolumab measured with a (SLE) Responder Index (SRI-4) [Furie, R. et al. Arthritis Rheumatism 2009, 61 (9), 1143-1151 , PMID: 19714615] (placebo adjusted) in patients with IFN-1 high at baseline is modest, i.e., 6 percentage points. In TULIP 2 the efficacy of anifrolumab (placebo adjusted) measured with SRI-4 is numerically higher in patients with IFN-1 high at baseline than in patients with IFN-1 low, i.e., 17.3 and 11.2 percentage points, respectively. The TULIP 2 manuscript authors indicated that because the number of IFN-1 low patients was small (30 in low vs 150 in high, 17%), the effect of anifrolumab in such patients requires further analysis. The pooled phase 3 studies TULIP 1 & 2 allows comparisons of greater sample size for the IFN-1 low group, (i.e., 122 patients in IFN-1 low treated with 300 mg or placebo, 60 and 62 patients, respectively) [Vital, EM. et al., Ann Rheum Dis 2022, 81 , 951-961 , PMID:35338035], There was no treatment effect on SRI-4 in the IFN-1 low group (45.2% and 45.3% for the 300 mg anifrolumab and placebo, respectively) while a modest effect of 9 percentage points on BICLA (British Isles Lupus Assessment Group- based Composite Lupus Assessment) was observed (46.8% and 37.5%, for the 300 mg anifrolumab and placebo, respectively.
The FDA analysis of the NDA on anifrolumab 150, 300 and 1000 mg led to their conclusion "that while neutralization of the IFN-1 gene signature reflects the direct pharmacological effect of anifrolumab and there is a clear dose-dependent PD response, its clinical relevance is still unclear as the PD response is higher in the non-responders on the 300 mg arm compared to the responders on the 150 mg arm" [FDA SAPHNELO multi-discipline review, p 44-47 (CENTER FOR DRUG EVALUATION AND RESEARCH, BLA 761123
Multi-disciplinary Review and Evaluation, Saphnelo (anifrolumab-fnia) for adults with SLE, version date: October 12, 2018)]. This is based on the FDA analysis of the PD response (neutralization of Type-1 gene signature and responder/non-responder analysis for SRI-4 and BICLA).
In summary, while AZ indicates that further studies are warranted to investigate the difference in efficacy between IFN-1 high and low population, the FDA gave a broad SLE population label indication. This suggests that it is not obvious that by targeting the IFN type 1 pathway specifically, you have a benefit only in IFN-high patients but also have a benefit in IFN-low patients too. Conversely, it is not obvious that by targeting mechanisms not directly related to modulating the type 1 interferon pathway one could expect to see only a beneficial effect in IFN-high patients with SLE but not in IFN-low patients which is what is observed with cenerimod (figure 1c).
Iberdomide is a high affinity cereblon ligand that promotes proteasomal degradation of transcription factors Ikaros and Aiolos. Aiolos is a B cell modulator and is required for maturation of plasma cells. Ikaros is required for development of B cells and plasmacytoid pDCs, which are important producers of IFN-a [Lipsky, PE. et al., Ann Rheum Dis 2022, 81 , 1136-1142, PMID:35477518],
Iberdomide doses of 0.15, 0.30 and 0.45 mg were investigated against placebo in a phase 2 study where 179 of 288 patients (62%) were IFN-1 high at baseline. This trial was not stratified according to gene signature at baseline, the highest proportion of IFN-1 high was in the 0.45 mg group (70%), and the lowest in the placebo group (58%) [Merrill, JT. et al., N Engl J Med 2022, 386, 1034-1045, PMID:35294813],
At week 24, the highest SRI-4 response (the primary end point) had occurred in 44 of 81 patients (54%) receiving the 0.45-mg dose of iberdomide and in 29 of 83 patients (35%) receiving placebo (adjusted difference, 19.4 percentage points). Iberdomide and placebo did not have meaningful differences with respect to most secondary end points. Among the patients with an IFN-1 high status, the responses occurred in 34 of 57 patients (60%) in the 0.45 mg iberdomide group vs 16 of 48 patients (33%) in the placebo group. Even if exploratory analysis indicates that the highest cut point for the IFN-1 subgroup (representing 31% of the total study population) was associated with the most enhanced relationship with response, providing a treatment difference of 54 percentage points vs placebo (5 out of 27 (20.0%) vs 17 out of 23 (74%)) [Lipsky, PE. et al., Ann Rheum Dis 2022, 81 , 1136-1142, PMID:35477518], still 10 of 24 patients (42%) with an IFN-1 low status responded to iberdomide 0.45mg. Analysis of changes in the biomarkers showed that the phase 2 SLE patients with an IFN-1 high status at baseline manifested a significant
reduction in the IFN signature as a result of active treatment, whereas those with low baseline IFN signature did not [[Lipsky, PE. et al., Ann Rheum Dis 2022, 81 , 1136-1142, PMID:35477518], Treatment with iberdomide was associated with a significant, dosedependent reduction in pDCs and mDCs, which are thought to be primary sources of type 1 IFNs.
Rontalizumab, despite targeting the IFN-1 pathway, was found to be more efficacious in IFN-1 low patients (Kalunian, K. et al., Ann Rheum Dis 2016, 75, 196-202, PMID: 26038091). This further highlights the complexity to identify responder patients’ subgroups.
Sifalimumab is a fully human, immunoglobulin G1 K monoclonal antibody that binds to and neutralizes most IFN-a subtypes. It was developed by AstraZeneca and its development was discontinued in favor of anifrolumab. Earlier clinical trials of sifalimumab have established its suppression of IFN-a-induced genes and have suggested favorable effects on clinical outcome measures [Petri, M. et al., Arthritis Rheumatism 2013, 65(4), 1011- 1021 , PMID:23400715],
Despite extensive investigations into the IFN pathway and its association with SLE, to date the association of S1 P1 receptor modulation and IFN signalling remains poorly explored. Early evidence linking IFN alpha with S1 P1 was published in 2006 (Shiow, L. et al., Nature 2006, 440, 540-544, PMID: 16525420). Here it was reported that mice treated with poly(l:C), a double-stranded RNA mimetic, which induces IFN signalling, lead to CD69 modulation and the subsequent inhibition of lymphocyte egress from lymph nodes via a down-regulation of the S1 P1 signalling pathway. This suggested that IFN signalling could modulate S1 P1 mediated lymphocyte migration. Teijaro (Teijaro, JR. et al., PNAS 2016, 113(5), 1351-1356, PMID: 26787880) further reported that sphingosine 1-phosphate (S1 P)- S1 PR1 signaling in plasmacytoid dendritic cells (pDCs) directly inhibits IFN-a autoamplification by induced degradation of the interferon alpha receptor 1 (IFNAR1) receptor, again suggesting that an S1 P1 receptor modulator could lead to a decrease in IFN mediated signalling. However, in mouse models of influenza it was reported that S1 P1 receptor signaling on pulmonary endothelial cells in vivo blunts but does not abolish IFN-a production [Teijaro, JR. et al., Cell 2011 , 146(6), 980-991 , PMID: 21925319],
The potential role of S1 P modulators in modulating IFN associated proteins in the context of SLE was recently investigated by Strasser et al. Efficacy in an MRL/lpr mouse model of SLE was demonstrated with a decrease in lymphocytes in the periphery and an improvement in survival. Further, a small exploratory study involving 13 patients diagnosed with SLE were treated with cenerimod for a period of 12 weeks. A large heterogeneity in IFN associated biomarkers between the patients in the study was observed and cenerimod
treatment led to a trend in the reduction of IFN associated biomarkers [Strasser, DS et al., RMD Open 2020, 6, e001261 , PMID: 32917831],
Together these data suggest a complex and contradictory interaction between the IFN-1 and S1 P1 signalling pathways in the context of disease. There was no previous evidence demonstrating that S1 P1 modulation can lead to an improvement in the health of patients with SLE, as measured by mSLEDAI-2K, who exhibit specifically an IFN-1 high gene signature and elevated IFN associated proteins.
Description of the Fiaures
Figure 1 shows:
A) A histogram showing the distribution of the type 1 IFN gene signature score at baseline from the CARE study of the combined placebo and cenerimod 4mg cohorts. Clearly visible is a bimodal distribution. The grey line depicts the cut-off between IFN-1 low and IFN-1 high at -0.5.
B) Boxplot depicting individual (IFN-1 high) patients represented as dots at baseline and at month 6 of treatment for the placebo and the 4 mg cenerimod treated groups from the CARE study showing the type 1 IFN gene signature score (IFN-1 score) that was measured for each individual from blood. In boxplots, the whiskers indicate the minimum and maximum range. A decrease in the mean value of the IFN-1 score in the cenerimod 4mg group is observed after 6 months compared to baseline, whereas there is a very small difference observed in the mean value is observed over 6 months in the placebo group.
C) Graph showing the least square (LS) mean change from baseline to 6 months in modified SLEDAI-2K (mSLEDAI-2K). The upper graph shows patients who were classified as IFN-1 high at baseline and compares placebo with cenerimod 4mg up to 6 months. The lower panel shows patients who were classified as IFN-1 low at baseline and compares placebo with cenerimod 4mg. No difference is observed between placebo and cenerimod 4mg in the IFN-1 low groups in mSLEDAI-2K at 6 months. A clear difference is observed in the IFN-1 high group in the decrease observed between cenerimod 4mg and placebo at 6 months compared to baseline.
Figure 2 shows:
Effect of placebo and cenerimod 4 mg on blood lymphocyte counts over the treatment period of 6 months. The mean change from baseline in lymphocyte count is displayed. Whereas placebo does not decrease blood lymphocyte counts, a fast
and sustained decrease is observed both in the IFN-1 high and IFN-1 low patient subgroups treated with cenerimod 4 mg.
Figure 3 shows:
A) boxplot depicting individual patients represented as dots at baseline and at month 6 of treatment for the placebo and the 4mg cenerimod treated groups from the CARE study showing the amount of IFN alpha protein in pg/ml that was measured for each individual from blood plasma. In boxplots, the whiskers indicate the minimum and maximum range. A decrease in the mean value of IFN alpha protein in the cenerimod 4mg group is observed after 6 months compared to baseline, whereas a slight elevation in the mean value is observed over 6 months in the placebo group.
B) IFN alpha protein in plasma in pg/ml from a healthy volunteer cohort (control) and from the placebo and 4mg cenerimod cohorts from the CARE study at baseline depicted in a boxplot. Individual patients are represented as dots. 95% of healthy volunteers have values below 0.1 pg/ml and this is represented by the line shown. This marks the cutoff point between high and low. The patient cohort has a higher level of IFN alpha protein than the healthy volunteer cohort.
C) The delta of the mSLEDAI-2K values at 6 months compared to baseline are depicted for the placebo and cenerimod 4mg cohorts from the CARE study as boxplots. The placebo and cenerimod 4mg cohorts are segregated into IFN alpha low and IFN alpha high groups according to their measured IFN alpha values at baseline. The decrease in mSLEDAI-2K score (i.e an improvement in the clinical readout) is similar for both the placebo and cenerimod 4mg IFN alpha protein low groups. The decrease in mSLEDAI-2K for the placebo IFN high group is small. However, the cenerimod 4mg IFN alpha protein high group shows a marked reduction in mSLEDAI-2K when compared to the other 3 groups.
Figure 4 shows:
A) boxplot depicting individual patients represented as dots at baseline and at month 6 of treatment for the placebo and the 4mg cenerimod treated groups from the CARE study showing the amount of the IFN gamma protein in pg/ml that was measured for each individual from blood plasma. In boxplots, the whiskers indicate the minimum and maximum range. A decrease in the mean value of IFN gamma protein in the cenerimod 4mg group is observed between baseline and after 6 months treatment, whereas a slight elevation in the mean value is observed over 6 months in the placebo group.
B) IFN gamma protein in plasma in pg/ml from a healthy volunteer cohort (control) and from the placebo and 4mg cenerimod cohorts from the CARE study at baseline depicted in a boxplot. Individual patients are represented as dots. 95% of healthy volunteers have values below 9.5pg/ml and this is represented by the line shown. This marks the cut-off point between high and low. The patient cohort has a higher level of IFN gamma protein than the healthy volunteer cohort.
C) The delta of the mSLEDAI-2K values at 6 months compared to baseline are depicted for the placebo and cenerimod 4mg cohorts from the CARE study as boxplots. The placebo and cenerimod 4mg cohorts are segregated into IFN gamma low and IFN gamma high groups according to their measured IFN gamma values at baseline. The decrease in mSLEDAI-2K score (i.e., an improvement in the clinical readout) is similar for both the placebo and cenerimod 4mg IFN gamma protein low groups. The decrease in mSLEDAI-2K for the placebo IFN gamma high group is small. However, the cenerimod 4mg IFN gamma high group shows a marked reduction in mSLEDAI-2K when compared to the other 3 groups.
Figure 5 shows:
A significant correlation of plasma IFN-oc levels with the blood IFN-1 gene expression score was observed (A). Cenerimod 4 mg treatment for 6 months decreased the IFN-1 gene expression score both in IFN-1 high and low status patients. In contrast, placebo treatment for 6 months rather increased the IFN-1 gene expression score both in IFN-1 high and low status patients (B).
Detailed Description of the Invention
Various embodiments of the invention are presented hereafter:
1) A first embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease in a subject, wherein the subject has a high type 1 interferon (IFN-1) gene signature score.
The term “has” in the context of “the subject has a high type 1 interferon (IFN-1) gene signature score”, refers to a subject that has and/or that is identified as having and/or that is diagnosed as having a high type 1 interferon (IFN-1) gene signature score.
2) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 1), wherein the subject has a high type 1 interferon (IFN-1) gene signature score at treatment onset.
3) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44, and IFI44L; or e) IFI6, RSAD2, IFI44L, and IFI27; or f) IFI6, RSAD2, IFI44, and IFI27; or g) RSAD2, IFI44, IFI44L, and IFI27; or h) IFI6, IFI44, IFI44L, and IFI27; or i) I FI6, MX1 , IFIT1 , and HERC5; or j) EIF2AK2, MX1 , and IFIT1 ; or k) EIF2AK2, IFI44, and IFIT1. l) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or m) RSAD2, IFI27, IFIT1 , and HERC5.
Group a) is disclosed in WO 2020/084591 ; group b) in WO 2022/074123 and in Yao Y, et al. Human Genomics and Proteomics 2009; article ID 374312, doi:10.4061/2009/374312; groups c) to h) in WO 2011/028933 and in Furie R, et al. Arthritis & Rheumatology 2017; 69(2) 376-386; group i) in Westra H-J, et al. Nature Genetics 2013; 45(10) 1238-1243, doi:10.1038/ng.2756; group j) in Niewold, T et al. Genes and Immunity 2007; 8 492-502, doi: 10.1038/sj. gene.6364408; group k) in Kirou, K. et al. Arthritis & Rheum. 2005; 52(5) 1491-1503; and groups I) and m) in Northcott M, et al. Lupus Science & Medicine 2022;9:e000625; doi:10.1136/lupus-2021 -000625.
4) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or
b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or e) RSAD2, IFI27, IFIT1 , and HERC5.
5) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
6) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
7) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on the type 1 interferon-associated genes EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
8) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) or 2), wherein the type 1 interferon gene signature score is calculated based on the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5.
The type 1 interferon gene signature score of a subject can be calculated according to any of the methods given in WO 2011/028933, WO 2020/084591 , Furie R, et al. Arthritis & Rheumatology 2017; 69(2) 376-386 or Northcott M, et al. Lupus Science & Medicine 2022;9:e000625; doi:10.1136/lupus-2021 -000625. Northcott et al. describes especially a method to calculate the IFN-1 gene signature score of a subject based on the 4 genes RSAD2, IFI27, IFIT1 , and HERC5 and further discloses an IFN-1 gene signature score cutoff value of -0.5 between subjects having a low and a high IFN-1 gene signature score.
Northcott et al. further refers to an IFN-1 test that is commercially available from DxTerity Diagnostics Inc. Especially, the type 1 interferon gene signature score of a subject can be calculated by the method originally developed by DxTerity Diagnostics Inc. by (i) measuring the gene (RNA) expression levels of the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5 in a blood sample of a subject (for instance by measuring respective peak height in capillary electrophoresis electropherograms); (ii) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject; (iii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof; (iv) calculating the normalized expression for each of the four type 1 interferon- associated genes according to Formula (I); and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the four type 1 interferon-associated genes.
Normalized Expression Gene i = l_og2 (Height Gene i) - Mean (l_og2 (Normalizer Genes Height))
Formula (I)
An important property of the IFN-1 gene signature is the bimodal distribution in subjects with systemic lupus erythematosus (SLE) allowing separation into subjects with a high type 1 interferon (IFN-1) gene signature score (IFN-1 high subjects) and subjects with a low score (IFN-1 low subjects) [El-Sherbiny, YM. et al., Scientific Reports 2018, 8, 5793, D0l:10.1038/s41598-018-24198-1 , PMID: 29643425], Subjects having a high IFN-1 gene signature score can be defined as subjects with an IFN-1 gene signature score above a threshold value (or alternatively “cut-off value”); those having a low IFN-1 gene signature score can be defined as subjects with an IFN-1 gene signature score at or below the threshold value. The threshold or cut-off value can be defined in accordance with any of the methods known in the art (for instance WO 2011/028933 or Northcott M, et al. Lupus Science & Medicine 2022;9:e000625; doi:10.1136/lupus-2021 -000625). Especially the threshold I cut-off value can be defined relative to the IFN-1 gene signature score of healthy humans: for instance, the threshold I cut-off value may be any IFN-1 gene signature score value between 1 .8 to 4.0 (notably 2.0 to 3.0) standard deviations above the arithmetic mean value from at least 20 (notably at least 200) healthy humans. Notably, the threshold I cut-off value of the IFN-1 gene signature score may be defined as 2 standard deviations above the arithmetic mean value from at least 100 (notably at least 300) healthy humans. Notably, the IFN-1 gene signature scores of subjects (especially patients) and of
healthy humans (for determination of the cut-off value) are calculated using the same method of IFN-1 gene signature score determination.
Abedi et al. (DxTerity) have compared in a study the relative performance of four different IFN gene signatures in a cohort of 687 participants with self-reported systemic lupus erythematosus (SLE). The frequently used 4-gene IFN signature of IFI27, IFI44, IFI44L, and RSAD2 identified 36.5% of the participants as IFN high and 63.5% as IFN low. Three other literature reported IFN signatures (IFI6, MX1 , IFIT1 , and HERC5; EIF2AK2, MX1 , and IFIT1 ; and EIF2AK2, IFI44, and IFIT1) provided similar classification results with participants being assigned to the same IFN sub-group (IFN high/IFN low) over 90% of the time, and nearly identical patient distributions; all four IFN gene signatures resulted in a similar bimodal IFN-1 gene signature score distribution as found with the 4 genes RSAD2, IFI27, IFIT1 , and HERC5 and shown in Fig. 1A (Abedi M et al. Annals of the Rheumatic Diseases 2018; 77 (Suppl. 2: EULAR 2018 abstracts) 885-886 (#SAT0041), DOI: 10.1136/annrheumdis-2018-eular.3758 and corresponding poster: Abedi M, Comparison Of Different Type 1 IFN Signatures Demonstrates Concordance In A Real World, Home Monitored Systemic Lupus Erythematosus Cohort, EULAR 2018, poster #SAT0041).
9) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 8), wherein the type 1 interferon gene signature score of the subject is at or above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
The minimum of the bimodal distribution curve may be obtained by determining the number of SLE patients with a given type 1 interferon gene signature score as a function of the type 1 interferon gene signature score. The bimodal distribution curve may be based on the type 1 interferon gene signature scores of at least 50, of at least 100, of at least 200, or (preferably) of at least 300 SLE patients. The bimodal distribution curve may be obtained from current (e.g., from data collected less than 1 year ago) and/or from historical (e.g., from data collected more than 1 year ago) data on type 1 interferon gene signature scores in SLE patients.
10) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 9), wherein the type 1 interferon gene signature score of the subject is at least 0.5 units, at least 1 unit, at least 2 units or at least 3 units (especially at least 1 unit) above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
11) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 8), wherein the subject has a type 1 interferon gene signature score that is higher than the type 1 interferon gene signature score of a (representative) healthy subject.
12) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 8), wherein the type 1 interferon gene signature score of the subject is above a threshold value.
13) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 12), wherein the threshold value is an IFN-1 gene signature score value that is selected from values between 1.8 to 4.0 (i.e. 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0; especially 2.0 to 3.0, and notably 2.0 to 2.5) standard deviations above the arithmetic mean of the IFN-1 gene signature score values from at least 20, at least 50, at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
14) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 12), wherein the threshold value of the IFN-1 gene signature score is 2 standard deviations above the arithmetic mean value from at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
15) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 12), wherein the threshold value of the IFN-1 gene signature score is between -1.0 and 0 (especially about - 0.5).
16) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 12), wherein the threshold value of the IFN-1 gene signature score is -0.5.
17) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 16), wherein the type 1 interferon gene signature score of the subject is calculated (determined) by a method comprising the following steps:
(i) measuring the gene (RNA) expression levels of the type 1 interferon-associated genes (especially of RSAD2, IFI44, IFI44L, and IFI27; or of RSAD2, IFI27, IFIT1 , and HERC5;
and notably of RSAD2, IFI27, IFIT1 , and HERC5) in a blood sample of a subject (notably by measuring respective peak height by capillary electrophoresis);
(ii) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject;
(iii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof;
(iv) calculating the normalized expression for each of the type 1 interferon-associated genes according to Formula (I):
Normalized Expression Gene i = l_og2 (Height Gene i) - Mean (l_og2 (Normalizer Genes Height))
Formula (I) and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the type 1 interferon-associated genes.
18) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 3) to 16), wherein the type 1 interferon gene signature score of the subject is calculated (determined) by a method comprising the following steps:
(i) measuring the gene (RNA) expression levels of the type 1 interferon-associated genes (especially of RSAD2, IFI44, IFI44L, and IFI27; or of RSAD2, IFI27, IFIT1 , and HERC5; and notably of RSAD2, IFI27, IFIT1 , and HERC5) in a blood sample of a subject (notably by measuring respective peak height by capillary electrophoresis);
(ii) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject;
(iii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof;
(iv) calculating the normalized expression for each of the four type 1 interferon-associated genes according to Formula (I):
Normalized Expression Gene i = l_og2 (Height Gene i) - Mean (l_og2 (Normalizer Genes Height))
Formula (I) and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the four type 1 interferon-associated genes.
19) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with the S1 Pi receptor modulator), the method comprising: a) providing a biological sample (especially a blood sample or a serum sample, and notably a blood sample) from the subject; b) assaying gene expression of at least three (especially at least four) type 1 interferon- associated genes selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6 (especially IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6, and notably EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15) in the biological sample; c) determining a normalised expression value of each assayed gene; d) calculating a type 1 interferon gene signature score by averaging the normalised expression values; and e) treating the subject with the S1 Pi receptor modulator when the type 1 interferon gene signature score of the subject is higher than a threshold value.
20) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 19), wherein the subject has a type 1 interferon gene signature score that is higher than a threshold value at treatment onset and/or is higher than the type 1 interferon gene signature score in a biological sample from a healthy subject at treatment onset.
Especially, the subject has a type 1 interferon gene signature score that is higher than a threshold value at treatment onset.
21) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) or 20), wherein the biological sample is a blood sample.
22) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19)
to 21), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44, and IFI44L; or e) IFI6, RSAD2, IFI44L, and IFI27; or f) IFI6, RSAD2, IFI44, and IFI27; or g) RSAD2, IFI44, IFI44L, and IFI27; or h) IFI6, IFI44, IFI44L, and IFI27; or i) IFI6, MX1 , IFIT1 , and HERC5; or j) EIF2AK2, MX1 , and IFIT1 ; or k) EIF2AK2, IFI44, and IFIT1. l) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or m) RSAD2, IFI27, IFIT1 , and HERC5.
23) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or e) RSAD2, IFI27, IFIT1 , and HERC5.
24) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) RSAD2, IFI44, IFI44L, and IFI27; or
b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
25) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
26) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein the type 1 interferon-associated genes for assaying gene expression are EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
27) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 21), wherein the type 1 interferon-associated genes for assaying gene expression are RSAD2, IFI27, IFIT1 , and HERC5.
28) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 27), wherein the gene expression is assayed by capillary electrophoresis (especially capillary electrophoresis suitable for nucleotide analysis).
29) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 27), wherein the gene expression of the type 1 interferon-associated genes is assayed by measuring peak height in capillary electrophoresis electropherograms.
30) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 29), wherein the normalized expression values are determined by (i) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject; (ii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof; and (iii) calculating the normalized expression value for each of the type 1 interferon-associated genes according to Formula (II)
Normalized Expression Gene i = l_og2 (Expression Level of Gene i) - Mean (Log2 (Expression Level of Normalizer Genes)) Formula (II).
In a preferred embodiment the normalized expression values are calculated based on peak heights (especially peak heights in capillary electrophoresis electropherograms) of the respective genes by using Formula (I).
31) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 30), wherein the type 1 interferon gene signature score of the subject is at or above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
The minimum of the bimodal distribution curve may be obtained by determining the number of SLE patients with a given type 1 interferon gene signature score as a function of the type 1 interferon gene signature score. The bimodal distribution curve may be based on the type 1 interferon gene signature scores of at least 50, of at least 100, of at least 200, or (preferably) of at least 300 SLE patients. The bimodal distribution curve may be obtained from current (e.g., from data collected less than 1 year ago) and/or from historical (e.g., from data collected more than 1 year ago) data on type 1 interferon gene signature scores in SLE patients.
32) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 31), wherein the type 1 interferon gene signature score of the subject is at least 0.5 units, at least 1 unit, at least 2 units or at least 3 units (especially at least 1 unit) above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
33) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 30), wherein the threshold value is an IFN-1 gene signature score value that is selected from values between 1.8 to 4.0 (i.e. 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0; especially 2.0 to 3.0, and notably 2.0 to 2.5) standard deviations above the arithmetic mean of the IFN-1 gene signature score values from at least 20, at least 50, at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
34) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 30), wherein the threshold value of the IFN-1 gene signature score is 2 standard
deviations above the arithmetic mean value from at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
35) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 19) to 30), wherein the threshold value of the IFN-1 gene signature score is selected from values between -1.0 and 0 (especially about -0.5, and notably -0.5).
36) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 35), wherein the threshold value of the IFN-1 gene signature score is -0.5.
37) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with the S1 Pi receptor modulator), the method comprising: a) providing a biological sample (especially a blood sample or a serum sample, and notably a blood sample) from the subject; b) assaying gene expression of the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5 in the biological sample (especially by measuring peak height in capillary electrophoresis electropherograms); c) determining a normalised expression value of each assayed gene by (i) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in the biological sample of the subject; (ii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof; and (iii) calculating the normalized expression value for each of the type 1 interferon-associated genes according to Formula (II)
Normalized Expression Gene i = l_og2 (Expression Level of Gene i) - Mean (Log2 (Expression Level of Normalizer Genes))
Formula (II); d) calculating a type 1 interferon gene signature score by averaging the normalised expression values; and e) treating the subject with the S1 Pi receptor modulator when the type 1 interferon gene signature score of the subject is higher than a threshold value, wherein the threshold value is selected from values between -1.0 and 0 (especially -0.5).
In a preferred embodiment the normalized expression values are calculated based on peak heights of the respective genes by using Formula (I).
38) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with the S1 Pi receptor modulator) in a subject, wherein at least three (especially at least four) type 1 interferon-associated genes are upregulated in the subject (especially in a biological sample from the subject), wherein the type 1 interferon-associated genes are selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6 (especially IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6, and notably EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15).
The upregulation of type 1 interferon-associated genes in the subject’s expression profile may be by any degree relative to that of a sample from a control (which may be from a sample that is not disease tissue of the subject or from a healthy person not afflicted with the type 1 interferon mediated disease) or may be relative to that of genes from the subject whose expression is not changed by the type 1 interferon mediated disease (so called housekeeping genes); especially relative to that of genes from the subject whose expression is not changed by the type 1 interferon mediated disease.
The degree of upregulation may be at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 300%, or more that of the control or control sample.
39) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 38), wherein the type 1 interferon-associated genes are upregulated in the subject at treatment onset.
40) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject:
a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44, and IFI44L; or e) IFI6, RSAD2, IFI44L, and IFI27; or f) IFI6, RSAD2, IFI44, and IFI27; or g) RSAD2, IFI44, IFI44L, and IFI27; or h) IFI6, IFI44, IFI44L, and IFI27; or i) IFI6, MX1 , IFIT1 , and HERC5; or j) EIF2AK2, MX1 , and IFIT1 ; or k) EIF2AK2, IFI44, and IFIT1. l) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or m) RSAD2, IFI27, IFIT1 , and HERC5.
41) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or e) RSAD2, IFI27, IFIT1 , and HERC5.
42) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
43) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
44) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three of the following type 1 interferon-associated genes are upregulated in the subject: EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
45) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 38) or 39), wherein at least three of the following type 1 interferon-associated genes are upregulated in the subject: RSAD2, IFI27, IFIT1 , and HERC5.
46) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease in a subject, wherein the concentration/level of interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is elevated compared to a healthy subject.
For clarity, “a subject, wherein the concentration/level of interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is elevated compared to a healthy subject” means a subject having, and/or identified as having, and/or diagnosed as having (especially in blood plasma of the subject) a concentration/level of interferon-gamma (IFN- y) that is elevated compared to a healthy subject.
Especially, “a subject, wherein the concentration/level of interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is elevated compared to a healthy subject” means a subject having, and/or identified as having, and/or diagnosed as having (especially in blood plasma of the subject) a concentration/level of interferon-gamma (IFN- y) that is higher than the concentration/level of interferon-gamma (IFN-y) in 95% of healthy volunteers in a statistically representative group of the healthy volunteers.
47) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease in a subject, wherein the subject has a
concentration/level (especially a concentration/level in blood plasma) of interferon-gamma (IFN-y) above 9.5 pg/mL.
48) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease (that is responsive to treatment with the S1 Pi receptor modulator), the method comprising: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-gamma (IFN-y) in the biological sample; and c) treating the subject with the S1 Pi receptor modulator when the concentration/level of interferon-gamma (IFN-y) is elevated compared to the concentration/level of interferon- gamma (IFN-y) in a biological sample from a healthy subject and/or is above 9.5 pg/mL.
49) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 48), wherein the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is/are elevated compared to a healthy subject.
50) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 48), wherein the subject has a concentration/level (especially a concentration/level in blood plasma) of interferon-alpha (IFN-a ) above 0.1 pg/mL and/or of interferon-gamma (IFN-y) above 9.5 pg/mL.
51) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method according to any one of embodiments 19) to 37), wherein the method further comprises: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the biological sample; and c) treating the subject with the S1 Pi receptor modulator when the concentration/level of interferon-alpha (IFN-a ) and/or of interferon-gamma (IFN-y) is elevated compared to the concentration/level in a biological sample from a healthy subject.
For clarity, treatment of the subject with the S1 Pi receptor modulator according to dependent embodiment 51) requires both conditions to be fulfilled: (i) that the type 1 interferon gene signature score of the subject is higher than the respective threshold value and (ii) that the concentration/level of interferon-alpha (IFN-a ) and/or of interferon-gamma (IFN-y) is elevated compared to the concentration/level in a biological sample from a healthy subject.
52) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method according to any one of embodiments 19) to 37), wherein the method further comprises: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the biological sample; and c) treating the subject with the S1 Pi receptor modulator when the concentration/level of interferon-alpha (IFN-a ) is above 0.1 pg/mL and/or when the concentration/level of interferon-gamma (IFN-y) is above 9.5 pg/mL.
For clarity, treatment of the subject with the S1 Pi receptor modulator according to dependent embodiment 52) requires both conditions to be fulfilled: (i) that the type 1 interferon gene signature score of the subject is higher than the respective threshold value and (ii) that the concentration/level of interferon-alpha (IFN-a ) is above 0.1 pg/mL and/or that the concentration/level of interferon-gamma (IFN-y) is above 9.5 pg/mL.
53) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 52), wherein the S1 Pi receptor modulator is selected from fingolimod, ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof (especially from ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof, and notably from ozanimod, siponimod, ponesimod, cenerimod, or a pharmaceutically acceptable salt thereof).
Fingolimod (also known as FTY720, Gilenya, Tascenso ODT, 2-amino-2-[2-(4- octylphenyl)ethyl]propan-1 ,3-diol) is a S1 P receptor modulator that binds to several S1 P receptors. Fingolimod is used as a hydrochloride salt, is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and is available as hard capsules in strength of 0.25 mg and 0.5 mg. Alternatively, Fingolimod is used as a
lauryl sulfate salt, is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and is available as orally disintegrating tablets in strength of 0.25 mg and 0.5 mg.
Ozanimod (also known as RPC1063, Zeposia, 5-(3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3- dihydro-1 /-/-inden-4-yl}-1 ,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile) is a S1 P receptor modulator that selectively binds to S1 Pi and S1 P5 receptors. Ozanimod is used as a hydrochloride salt, is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and moderately to severely active ulcerative colitis and is available as capsules in strengths of 0.23 mg, 0.46 mg, and 0.92 mg (based on the free base and equivalent to 0.25 mg, 0.5 mg, and 1 mg ozanimod hydrochloride salt). The recommended maintenance dosage is 0.92 mg orally once daily.
Siponimod (also known as BAF312, MAYZENT, 1-[[4-[(1E)-1-[[[4-Cyclohexyl-3- (trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]-3-azetidinecarboxylic acid) is a dual S1 Pi and S1 P5 receptor modulator. Siponimod is used as a (2E)-2- butenedioate (2:1 mixture), is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and is available as tablets in strengths of 0.25 mg, 1 mg, and 2 mg. The recommended maintenance dosage is 1 mg (in patients with a CYP2C9*1/*3 or *21* genotype) or 2 mg orally once daily.
Ponesimod (also known as ACT-128800, PONVORY, (2Z,5Z)-5-[3-chloro-4-[(2R)-2,3- dihydroxypropoxy]benzylidene]-3-(2-methylphenyl)-2-(propylimino)-1 ,3-thiazolidin-4-one) is a selective modulator of the S1 Pi, S1 P4, and S1 P5 receptor. Ponesimod is approved by the U.S. Food & Drug administration for the treatment of relapsing forms of multiple sclerosis and is available as tablets in strengths of 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, and 20 mg. The recommended maintenance dosage is 20 mg orally once daily.
Cenerimod (also known as ACT-334441 , (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)- [1 ,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1 ,2-diol) is a selective S1 Pi receptor modulator. Cenerimod is developed for the treatment of systemic lupus erythematosus and was used in a clinical phase 2b study as tablets in strengths of 0.5 mg, 1 mg, 2 mg, and 4 mg.
Etrasimod (also known as APD334, 2-[(3R)-7-[[4-cyclopentyl-3-
(trifluoromethyl)phenyl]methoxy]-1 ,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid) is an oral, once-a-day selective modulator of S1 Pi, S1 P4, and S1 P5. Etrasimod is being investigated for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata and is used as tablets in strengths of 2 mg.
54) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 52), wherein the S1 Pi receptor modulator is selected from ozanimod, siponimod, ponesimod, and cenerimod, or a pharmaceutically acceptable salt thereof.
55) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 52), wherein the S1 Pi receptor modulator is cenerimod.
56) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 55), wherein cenerimod is comprised in a pharmaceutical dosage form for oral administration (especially in a tablet formulation, notably in a film coated tablet).
57) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 55) or 56), wherein cenerimod is comprised in the pharmaceutical dosage form in a unit dose of 4 mg (especially 4.0 mg).
The term “unit dose”, as used herein, refers to the amount of an active pharmaceutical ingredient (especially cenerimod) that is administered and/or is to be administered to a subject in a single dose. As an example, a unit dose is the amount of an active pharmaceutical ingredient (especially cenerimod) in a tablet or capsule (especially a tablet) for oral administration in case a single tablet or capsule is administered and/or is to be administered to the subject per administration.
58) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 55) to 57), wherein cenerimod is to be administered and/or is administered to a patient once per day (once daily).
59) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 55) to 58), wherein cenerimod is to be administered and/or is administered to a subject for a treatment period of at least 6 months (especially at least 12 months, and notably at least 60 months).
The term “treatment period”, as used herein (especially in relation to cenerimod), refers to the period between the first day of a treatment and the last day of an uninterrupted treatment with an active pharmaceutical ingredient (especially in relation to cenerimod), a pharmaceutical composition and/or a medicament, wherein a treatment is “uninterrupted” if
it is in accordance with a regularly repeating dosing scheme such as, for example, once daily. For instance, if cenerimod is administered and/or is to be administered once daily for a treatment period of 6 months, this means that cenerimod is administered and/or is to be administered once at every day of the 6 months period.
60) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 55) to 59), wherein cenerimod is to be administered and/or is administered to a subject chronically.
The term “chronical treatment” (or “chronically”) refers to a treatment period starting with the first day of treatment with the respective active pharmaceutical ingredient (especially cenerimod) and ending on the day on which a further continuation of the treatment of the subject with the active pharmaceutical ingredient is no longer feasible or indicated. The treatment of the subject with the active pharmaceutical ingredient might be for instance no longer feasible or indicated for reasons such as side effects of the treatment, changes of the health condition of the subject (requiring for instance a different medication), changes of other relevant circumstances in the life of a subject, death of the subject and the like. Especially, the term “chronical treatment” (or “chronically”) refers to a treatment period of at least 10 years, starting with the first day of treatment with the respective active pharmaceutical ingredient (especially cenerimod) until a further continuation of the treatment of the subject with the active pharmaceutical ingredient is not feasible or indicated.
The term “treatment onset” refers to the first day of treatment with the respective active pharmaceutical ingredient (especially the S1 Pi receptor modulator; and notably cenerimod).
The term “type 1 interferon mediated disease” means a disease that is linked or related to and/or has a common cause with (especially that is linked to and/or has a common cause with) a high type 1 interferon (IFN-1) gene signature score in at least some of the subjects suffering from the disease.
61) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 60), wherein the type 1 interferon mediated disease is selected from the group consisting of systemic lupus erythematosus, discoid lupus, lupus nephritis, glomerulonephritis, type I diabetes, inflammatory bowel disease (including Crohn’s disease, ulcerative colitis, and Celiac’s disease), multiple sclerosis, autoimmune thyroiditis, scleroderma, psoriasis, primary Sjogren’s disease, systemic sclerosis, rheumatoid arthritis, transplant rejection,
dermatomyositis, polymyositis, idiopathic inflammatory myositis, sarcoidosis, Aicardi- Goutieres syndrome, vasculitis, Sting associated vasculopathy with onset in infancy (SAVI) or chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE).
The S1 Pi receptor modulator (especially cenerimod) may be administered for the treatment of a type 1 interferon mediated disease or prophylactically in order to reduce the risk of developing a type 1 interferon mediated disease and/or to delay the onset of the symptoms.
The term “treat” or “treatment" or “treating” used with reference to a disease means either that said disease is cured in the subject; or that, although the subject remains affected by the disease, part or all of the symptoms of said disease are either reduced or eliminated.
The term “prevent” or “prevention" or “preventing” (or alternatively “prophylaxis” or “prophylactical(ly)”) used with reference to a disease means that the risk of developing said disease in the subject is reduced and/or that the onset of one or more symptoms of said disease in the subject is delayed.
62) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 60), wherein the type 1 interferon mediated disease is systemic lupus erythematosus and/or lupus nephritis.
63) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 60), wherein the type 1 interferon mediated disease is systemic lupus erythematosus.
64) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 60), wherein the type 1 interferon mediated disease is lupus nephritis, cutaneous lupus, or lupus with central nervous system (CNS) manifestations.
65) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) is reached after 12 months treatment of the subject (especially of a subject having SLE) with the S1 Pi receptor modulator (especially cenerimod).
The mSLEDAI-2K score is based on the SLEDAI-2K (Gladman DD, et al. J Rheumatol 2002; 29(2) 288-291), modified to exclude leukopenia (Hermann V, et al. Lupus Science &
Medicine 2019;6:e000354. doi:10.1136/lupus-2019-000354; ClinicalTrials.gov Identifier: NCT03742037).
The term “baseline”, as used herein in connection with a value, a score, an index, or the like (such as, for instance, a type 1 interferon (IFN-1) gene signature score or mSLEDAI-2K etc.), refers to the value, score, index, or the like as measured, calculated or otherwise determined before (especially closely before and notably immediately before) treatment onset with the active pharmaceutical ingredient (such as the S1 Pi receptor modulator or cenerimod).
66) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) of at least 2 points is reached after 12 months treatment of the subject (especially of a subject having SLE) with the S1 Pi receptor modulator (especially cenerimod).
67) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) of at least 4 points is reached after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially cenerimod) in at least 30% of the subjects.
68) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 67), wherein the reduction from baseline in mSLEDAI-2K is reached in at least 50% of the subjects.
69) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to embodiment 67), wherein the reduction from baseline in mSLEDAI-2K is reached in at least 70% of the subjects.
70) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 1 point lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
71) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 1.5 points lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
72) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 64), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 2 points lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
73) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 72), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially with cenerimod) is reached in at least 30 % of the subjects.
74) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 72), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially with cenerimod) is reached in at least 50 % of the subjects.
75) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 72), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially with cenerimod) is reached in at least 70 % of the subjects.
76) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 72), wherein the probability of a response on SRI-4 after 12 months treatment of a subject (especially of a subject having SLE) is higher (especially statistically significant higher) in a subject treated with the S1 Pi receptor modulator (especially with cenerimod) than in a subject treated with placebo.
A response on SLE responder index (SRI)-4 is defined as: reduction of at least 4 points in the mSLEDAI-2K compared to baseline; and no new BILAG A organ domain score and not more than one new BILAG B organ domain score compared to baseline; and no worsening from baseline in subjects’ lupus disease activity, where worsening is defined by an increase >0.30 points on a 3-point Physician’s Global Assessment (PGA) visual analogue scale (VAS).
The BILAG (British Isles Lupus Assessment Group) score is defined in Romero-Diaz J et al Arthritis Care Res (Hoboken). 2011 Nov; 63 Suppl 11 (0 11):S37-46. doi: 10.1002/acr.20572.
The Physician’s Global Assessment (PGA) is a visual analog scale (VAS) using 3 benchmarks for assessing disease activity over the last 2 weeks (Luijten KMAC et al, Autoimmunity Reviews Volume 11 , Issue 5, March 2012, Pages 326-329). Mild flare will score 1 .0 point, moderate flares will score a 2.0-2.5 point and severe flares will score a 3 on the 0-3 analog scale.
77) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 76), wherein the time to first confirmation of a 4-month sustained mSLEDAI-2K response (defined as a reduction of at least 4 points from baseline) is shorter (especially statistically significant shorter) in subject(s) treated with the S1 Pi receptor modulator (especially with cenerimod) than in subject(s) treated with placebo.
78) A further embodiment of the invention relates to cenerimod, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 76), wherein the time from treatment onset with cenerimod to first confirmation of a 4-month sustained mSLEDAI-2K response (defined as a reduction of at least 4 points from baseline) is statistically significant shorter in subject(s) treated with cenerimod than in subject(s) treated with placebo.
79) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 76), wherein the time to first confirmation of a 4-month sustained response in mucocutaneous manifestations is shorter (especially statistically significant shorter) in subject(s) treated with the S1 Pi receptor modulator (especially with cenerimod) than in subject(s) treated with placebo.
The time to first confirmation of a 4-month sustained response in mucocutaneous manifestations is defined as:
- no increase in overall mSLEDAI-2K score; and
- remission (score of zero) from baseline in the mSLEDAI-2K score of mucocutaneous manifestations (i.e. rash, alopecia, muscoal ulcers).
80) A further embodiment of the invention relates to cenerimod, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 76), wherein the time from treatment onset with cenerimod to first confirmation of a 4-month sustained response in mucocutaneous manifestations is statistically significant shorter in subject(s) treated with cenerimod than in subject(s) treated with placebo.
81) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 80), wherein the S1 Pi receptor modulator is cenerimod, or a pharmaceutically acceptable salt thereof, and wherein a clinically proven effective amount of cenerimod is administered and/or is to be administered to the subject.
82) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human (especially a human patient).
The term “subject” includes any human or nonhuman animal. “Nonhuman animal” includes all vertebrates. Notably, the term “subject” refers to a human, and especially to a human patient.
83) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from a type 1 interferon mediated disease.
84) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from systemic lupus erythematosus and/or lupus nephritis.
85) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from systemic lupus erythematosus.
86) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from systemic lupus
erythematosus, and wherein the subject has a mSLEDAI-2K score > 6 and a clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
The clinical mSLEDAI-2K is the mSLEDAI-2K assessment score without the inclusion of points attributable to hematuria, proteinuria, pyuria, low complement, increased DNA binding, and thrombocytopenia.
87) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 81), wherein the subject is a human patient suffering from systemic lupus erythematosus, and wherein the subject has (i) a mSLEDAI-2K score > 6 and a clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers); (ii) a British Isles Lupus Assessment Group-2004 (BILAG) Grade B in > 2 organ systems or a BILAG Grade A in > 1 organ system; and (iii) Physician's Global Assessment (PGA) score > 1.0 on a 0 to 3 VAS.
88) A further embodiment of the invention relates to a S1 Pi receptor modulator (especially cenerimod), or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 1) to 87), wherein the subject is a subject receiving standard background therapy (wherein it is understood that such standard background therapy is suitable for the treatment of a type 1 interferon mediated disease, especially of systemic lupus erythematosus).
Standard background therapy for the treatment of systemic lupus erythematosus may be an antimalarial, such as hydroxychloroquine, chloroquine, or quinacrine; mycophenolate mofetil or mycophenolic acid; azathioprine; methotrexate; an oral corticosteroid, such as prednisone, prednisolone, hydrocortisone, methylprednisolone, or dexamethasone; belimumab; anifrolumab; or any other drug approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or a corresponding national regulatory agency and/or used as standard of care at the date of treatment onset with the S1 Pi receptor modulator.
Cenerimod can be used as medicament according to this invention, e.g. in the form of pharmaceutical compositions especially for enteral, or for parenteral administration.
Dosage forms suitable for enteral administration may be tablets or capsules (especially tablets) comprising a pharmaceutical composition comprising an efficacious amount of cenerimod, or a pharmaceutically acceptable salt thereof.
For avoidance of any doubt, it is understood that any pharmaceutical composition comprising cenerimod in a pharmaceutically effective amount may additionally comprise further conventional excipients and/or additives, which may be used alone or in combination.
Reference is made to the extensive literature on the subject for pharmaceutically acceptable excipients and procedures mentioned herein, see for example R.C. Rowe, P.J. Seskey, S.C. Owen, Handbook of Pharmaceutical Excipients, 5th edition, Pharmaceutical Press 2006; Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, “Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins],
Any reference to a S1 Pi receptor modulator in this specification is to be understood as referring also to the pharmaceutically acceptable salts of such a S1 Pi receptor modulator. Especially, any reference to cenerimod refers to cenerimod or a pharmaceutically acceptable salt form of cenerimod, preferably to cenerimod in free base form.
The term "pharmaceutically acceptable salt" refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound. For reference see for example ‘Handbook of Pharmaceutical Salts. Properties, Selection and Use.’, P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008 and ‘Pharmaceutical Salts and Cocrystals’, Johan Wouters and Luc Quere (Eds.), RSC Publishing, 2012.
Unless used regarding temperatures, the term “about” placed before a numerical value “X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X. In the particular case of temperatures, the term “about” placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C.
Whenever the word “between” is used to describe a numerical range, it is to be understood that the end points of the indicated range are explicitly included in the range.
It is understood that any embodiment relating to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment (especially treatment) of a type 1 interferon mediated disease also relates to the use of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment (especially treatment) of a type 1 interferon mediated disease; and to a method of prevention/prophylaxis or treatment (especially
treatment) of a type 1 interferon mediated disease, the method comprising administering to a subject in need thereof an effective amount (especially a pharmaceutically effective amount) of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof.
It is further understood that any embodiment relating to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease also relates to the use of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease; and to a method of preventing or treating (especially treating) a subject having a type 1 interferon mediated disease, the method comprising administering to a subject in need thereof an effective amount (especially a pharmaceutically effective amount) of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof.
89) A further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease, the method comprising administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject has a high type 1 interferon (IFN-1) gene signature score.
90) The method according to embodiment 89), wherein the subject has a high type 1 interferon (IFN-1) gene signature score at treatment onset.
91) The method according to any one of embodiments 89) or 90), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44, and IFI44L; or e) IFI6, RSAD2, IFI44L, and IFI27; or f) IFI6, RSAD2, IFI44, and IFI27; or g) RSAD2, IFI44, IFI44L, and IFI27; or h) IFI6, IFI44, IFI44L, and IFI27; or i) I FI6, MX1 , IFIT1 , and HERC5; or
j) EIF2AK2, MX1 , and IFIT1 ; or k) EIF2AK2, IFI44, and IFIT1. l) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or m) RSAD2, IFI27, IFIT1 , and HERC5.
92) The method according to any one of embodiments 89) or 90), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or e) RSAD2, IFI27, IFIT1 , and HERC5.
93) The method according to any one of embodiments 89) or 90), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
94) The method according to any one of embodiments 89) or 90), wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
95) The method according to any one of embodiments 89) or 90), wherein the type 1 interferon gene signature score is calculated based on the type 1 interferon-associated genes EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
96) The method according to any one of embodiments 89) or 90), wherein the type 1 interferon gene signature score is calculated based on the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5.
97) The method according to any one of embodiments 89) to 96), wherein the type 1 interferon gene signature score of the subject is at or above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
98) The method according to embodiment 97), wherein the type 1 interferon gene signature score of the subject is at least 0.5 units, at least 1 unit, at least 2 units or at least 3 units (especially at least 1 unit) above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
99) The method according to any one of embodiments 89) to 96), wherein the subject has a type 1 interferon gene signature score that is higher than the type 1 interferon gene signature score of a (representative) healthy subject.
100) The method according to any one of embodiments 89) to 96), wherein the type 1 interferon gene signature score of the subject is above a threshold value.
101) The method according to embodiment 100), wherein the threshold value is an IFN-1 gene signature score value that is selected from values between 1.8 to 4.0 (i.e. 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0; especially 2.0 to 3.0, and notably 2.0 to 2.5) standard deviations above the arithmetic mean of the IFN-1 gene signature score values from at least 20, at least 50, at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
102) The method according to embodiment 100), wherein the threshold value of the IFN-1 gene signature score is 2 standard deviations above the arithmetic mean value from at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
103) The method according to embodiment 100), wherein the threshold value of the IFN-1 gene signature score is between -1.0 and 0 (especially about -0.5).
104) The method according to embodiment 100), wherein the threshold value of the IFN-1 gene signature score is -0.5.
105) The method according to any one of embodiments 89) to 104), wherein the type 1 interferon gene signature score of the subject is calculated (determined) by a method comprising the following steps:
(i) measuring the gene (RNA) expression levels of the type 1 interferon-associated genes (especially of RSAD2, IFI44, IFI44L, and IFI27; or of RSAD2, IFI27, IFIT1 , and HERC5; and notably of RSAD2, IFI27, IFIT1 , and HERC5) in a blood sample of a subject (notably by measuring respective peak height by capillary electrophoresis);
(ii) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject;
(iii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof;
(iv) calculating the normalized expression for each of the type 1 interferon-associated genes according to Formula (I):
Normalized Expression Gene i = l_og2 (Height Gene i) - Mean (l_og2 (Normalizer Genes Height))
Formula (I) and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the type 1 interferon-associated genes.
106) The method according to any one of embodiments 91) to 104), wherein the type 1 interferon gene signature score of the subject is calculated (determined) by a method comprising the following steps:
(i) measuring the gene (RNA) expression levels of the type 1 interferon-associated genes (especially of RSAD2, IFI44, IFI44L, and IFI27; or of RSAD2, IFI27, IFIT1 , and HERC5; and notably of RSAD2, IFI27, IFIT1 , and HERC5) in a blood sample of a subject (notably by measuring respective peak height by capillary electrophoresis);
(ii) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject;
(iii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof;
(iv) calculating the normalized expression for each of the four type 1 interferon-associated genes according to Formula (I):
Normalized Expression Gene i = l_og2 (Height Gene i) - Mean (l_og2 (Normalizer Genes Height))
Formula (I) and (v) calculating the type 1 interferon gene signature score by averaging the normalized expression values of the four type 1 interferon-associated genes.
107) A further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising: a) providing a biological sample (especially a blood sample or a serum sample, and notably a blood sample) from the subject;
b) assaying gene expression of at least three (especially at least four) type 1 interferon- associated genes selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6 (especially IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6, and notably EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15) in the biological sample; c) determining a normalised expression value of each assayed gene; d) calculating a type 1 interferon gene signature score by averaging the normalised expression values; and e) administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof when the type 1 interferon gene signature score of the subject is higher than a threshold value.
108) The method according to embodiment 107), wherein the subject has a type 1 interferon gene signature score that is higher than a threshold value at treatment onset and/or is higher than the type 1 interferon gene signature score in a biological sample from a healthy subject at treatment onset.
109) The method according to any one of embodiments 107) or 108), wherein the biological sample is a blood sample.
110) The method according to any one of embodiments 107) to 109), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44, and IFI44L; or e) IFI6, RSAD2, IFI44L, and IFI27; or f) IFI6, RSAD2, IFI44, and IFI27; or g) RSAD2, IFI44, IFI44L, and IFI27; or h) IFI6, IFI44, IFI44L, and IFI27; or
i) I FI6, MX1 , IFIT1 , and HERC5; or j) EIF2AK2, MX1 , and IFIT1 ; or k) EIF2AK2, IFI44, and IFIT1. l) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or m) RSAD2, IFI27, IFIT1 , and HERC5.
111) The method according to any one of embodiments 107) to 109), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or e) RSAD2, IFI27, IFIT1 , and HERC5.
112) The method according to any one of embodiments 107) to 109), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
113) The method according to any one of embodiments 107) to 109), wherein one of the following groups of type 1 interferon-associated genes is selected for assaying gene expression: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
114) The method according to any one of embodiments 107) to 109), wherein the type 1 interferon-associated genes for assaying gene expression are EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
115) The method according to any one of embodiments 107) to 109), wherein the type 1 interferon-associated genes for assaying gene expression are RSAD2, IFI27, IFIT1 , and HERC5.
116) The method according to any one of embodiments 107) to 115), wherein the gene expression is assayed by capillary electrophoresis.
117) The method according to any one of embodiments 107) to 115), wherein the gene expression of the type 1 interferon-associated genes is assayed by measuring peak height in capillary electrophoresis electropherograms.
118) The method according to any one of embodiments 107) to 117), wherein the normalized expression values are determined by (i) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in a blood sample of the subject; (ii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof; and (iii) calculating the normalized expression value for each of the type 1 interferon-associated genes according to Formula (II)
Normalized Expression Gene i = l_og2 (Expression Level of Gene i) - Mean (Log2 (Expression Level of Normalizer Genes))
Formula (II).
119) The method according to any one of embodiments 107) to 118), wherein the type 1 interferon gene signature score of the subject is at or above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
120) The method according to embodiment 119), wherein the type 1 interferon gene signature score of the subject is at least 0.5 units, at least 1 unit, at least 2 units or at least 3 units (especially at least 1 unit) above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
121) The method according to any one of embodiments 107) to 118), wherein the threshold value is an IFN-1 gene signature score value that is selected from values between 1.8 to 4.0 (i.e. 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0; especially 2.0 to 3.0, and notably 2.0 to 2.5) standard deviations above the arithmetic mean of the IFN-1 gene signature score values from at least 20, at least 50, at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
122) The method according to any one of embodiments 107) to 118), wherein the threshold value of the IFN-1 gene signature score is 2 standard deviations above the arithmetic mean value from at least 100, at least 200, at least 300 or (preferably) at least 500 healthy humans.
123) The method according to any one of embodiments 107) to 118), wherein the threshold value of the IFN-1 gene signature score is selected from values between -1.0 and 0 (especially about -0.5, and notably -0.5).
124) The method according to any one of embodiments 107) to 118), wherein the threshold value of the IFN-1 gene signature score is -0.5.
125) A further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising: a) providing a biological sample (especially a blood sample or a serum sample, and notably a blood sample) from the subject; b) assaying gene expression of the type 1 interferon-associated genes RSAD2, IFI27, IFIT1 , and HERC5 in the biological sample (especially by measuring peak height in capillary electrophoresis electropherograms); c) determining a normalised expression value of each assayed gene by (i) measuring the gene expression levels of the three housekeeping (normalizer) genes ACTB, GAPDH, and TFRC in the biological sample of the subject; (ii) calculating the binary logarithm (log2) of the expression levels of each of the three housekeeping genes and the arithmetic mean thereof; and (iii) calculating the normalized expression value for each of the type 1 interferon-associated genes according to Formula (II)
Normalized Expression Gene i = l_og2 (Expression Level of Gene i) - Mean (Log2 (Expression Level of Normalizer Genes))
Formula (II); d) calculating a type 1 interferon gene signature score by averaging the normalised expression values; and e) administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof when the type 1 interferon gene signature score of the subject is higher than a threshold value, wherein the threshold value is selected from values between -1.0 and 0 (especially -0.5).
126) A further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the
subject in need thereof, wherein at least three (especially at least four) type 1 interferon- associated genes are upregulated in the subject (especially in a biological sample from the subject), wherein the type 1 interferon-associated genes are selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6 (especially IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6, and notably EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15).
127) The method according to embodiment 126), wherein the type 1 interferon-associated genes are upregulated in the subject at treatment onset.
128) The method according to any one of embodiments 126) or 127), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) IFI6, RSAD2, IFI44, IFI44L, and IFI27; or d) IFI6, RSAD2, IFI44, and IFI44L; or e) IFI6, RSAD2, IFI44L, and IFI27; or f) IFI6, RSAD2, IFI44, and IFI27; or g) RSAD2, IFI44, IFI44L, and IFI27; or h) IFI6, IFI44, IFI44L, and IFI27; or i) I FI6, MX1 , IFIT1 , and HERC5; or j) EIF2AK2, MX1 , and IFIT1 ; or k) EIF2AK2, IFI44, and IFIT1. l) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or m) RSAD2, IFI27, IFIT1 , and HERC5.
129) The method according to any one of embodiments 126) or 127), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, IFI44, IFI44L, HERC5, and PLSCR1 ; or
b) IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6; or c) RSAD2, IFI44, IFI44L, and IFI27; or d) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or e) RSAD2, IFI27, IFIT1 , and HERC5.
130) The method according to any one of embodiments 126) or 127), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) RSAD2, IFI44, IFI44L, and IFI27; or b) EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15; or c) RSAD2, IFI27, IFIT1 , and HERC5.
131) The method according to any one of embodiments 126) or 127), wherein at least three genes of at least one of the following groups of type 1 interferon-associated genes are upregulated in the subject: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
132) The method according to any one of embodiments 126) or 127), wherein at least three of the following type 1 interferon-associated genes are upregulated in the subject: EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15.
133) The method according to any one of embodiments 126) or 127), wherein at least three of the following type 1 interferon-associated genes are upregulated in the subject: RSAD2, IFI27, IFIT1 , and HERC5.
134) A further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein the concentration/level of interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is elevated compared to a healthy subject.
135) A further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor
modulator) in a subject, the method comprising administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof, wherein the subject has a concentration/level (especially a concentration/level in blood plasma) of interferon-gamma (IFN-y) above 9.5 pg/mL.
136) A further embodiment of the invention relates to a method for the prophylaxis or treatment (especially treatment) of a type 1 interferon mediated disease (especially a type 1 interferon mediated disease that is responsive to treatment with a S1 Pi receptor modulator) in a subject, the method comprising: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-gamma (IFN-y) in the biological sample; and c) administering a pharmaceutically effective amount of a S1Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof when the concentration/level of interferon-gamma (IFN-y) is elevated compared to the concentration/level of interferon-gamma (IFN-y) in a biological sample from a healthy subject and/or is above 9.5 pg/mL.
137) The method according to any one of embodiments 89) to 136), wherein the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the subject (especially in blood plasma of the subject) is/are elevated compared to a healthy subject.
138) The method according to any one of embodiments 89) to 136), wherein the subject has a concentration/level (especially a concentration/level in blood plasma) of interferonalpha (IFN-a ) above 0.1 pg/mL and/or of interferon-gamma (IFN-y) above 9.5 pg/mL.
139) The method according to any one of embodiments 107) to 125), wherein the method further comprises: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the biological sample; and c) administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof when in addition to the other condition the concentration/level of interferon-alpha (IFN-a ) and/or of interferon-
gamma (IFN-y) is elevated compared to the concentration/level in a biological sample from a healthy subject.
140) The method according to any one of embodiments 107) to 125), wherein the method further comprises: a) providing a biological sample (especially a plasma sample) from the subject; b) measuring the concentration/level of interferon-alpha (IFN-a) and/or interferon-gamma (IFN-y) in the biological sample; and c) administering a pharmaceutically effective amount of a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, to the subject in need thereof when in addition to the other condition the concentration/level of interferon-alpha (IFN-a ) is above 0.1 pg/mL and/or when the concentration/level of interferon-gamma (IFN-y) is above 9.5 pg/mL.
141) The method according to any one of embodiments 89) to 140), wherein the S1 Pi receptor modulator is selected from fingolimod, ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof (especially from ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof, and notably from ozanimod, siponimod, ponesimod, cenerimod, or a pharmaceutically acceptable salt thereof).
142) The method according to any one of embodiments 89) to 140), wherein the S1 Pi receptor modulator is selected from ozanimod, siponimod, ponesimod, and cenerimod, or a pharmaceutically acceptable salt thereof.
143) The method according to any one of embodiments 89) to 140), wherein the S1 Pi receptor modulator is cenerimod.
144) The method according to embodiment 143), wherein cenerimod is comprised in a pharmaceutical dosage form for oral administration (especially in a tablet formulation, notably in a film coated tablet).
145) The method according to any one of embodiments 143) or 144), wherein cenerimod is comprised in the pharmaceutical dosage form in a unit dose of 4 mg (especially 4.0 mg).
146) The method according to any one of embodiments 143) to 145), wherein cenerimod is to be administered and/or is administered to a patient once per day (once daily).
147) The method according to any one of embodiments 143) to 146), wherein cenerimod is to be administered and/or is administered to a subject for a treatment period of at least 6 months (especially at least 12 months, and notably at least 60 months).
148) A further embodiment of the invention relates to a S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 143) to 147), wherein cenerimod is to be administered and/or is administered to a subject chronically.
149) The method according to any one of embodiments 89) to 148), wherein the type 1 interferon mediated disease is selected from the group consisting of systemic lupus erythematosus, discoid lupus, lupus nephritis, glomerulonephritis, type I diabetes, inflammatory bowel disease (including Crohn’s disease, ulcerative colitis, and Celiac’s disease), multiple sclerosis, autoimmune thyroiditis, scleroderma, psoriasis, primary Sjogren’s disease, systemic sclerosis, rheumatoid arthritis, transplant rejection, dermatomyositis, polymyositis, idiopathic inflammatory myositis, sarcoidosis, Aicardi- Goutieres syndrome, vasculitis, Sting associated vasculopathy with onset in infancy (SAVI) or chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE).
150) The method according to any one of embodiments 89) to 148), wherein the type 1 interferon mediated disease is systemic lupus erythematosus and/or lupus nephritis.
151) The method according to any one of embodiments 89) to 148), wherein the type 1 interferon mediated disease is systemic lupus erythematosus.
152) The method according to any one of embodiments 89) to 148), wherein the type 1 interferon mediated disease is lupus nephritis, cutaneous lupus, or lupus with central nervous system (CNS) manifestations.
153) The method according to any one of embodiments 89) to 152), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) is reached after 12 months treatment of the subject (especially of a subject having SLE) with the S1 Pi receptor modulator (especially cenerimod).
154) The method according to any one of embodiments 89) to 152), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) of at least 2 points (especially at least 4 points) is reached after 12 months treatment of the subject (especially of a subject having SLE) with the S1 Pi receptor modulator (especially cenerimod).
155) The method according to any one of embodiments 89) to 152), wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) of at least 4 points is reached after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially cenerimod) in at least 30% of the subjects.
156) The method according to any one of embodiments 153) to 155), wherein the reduction from baseline in mSLEDAI-2K is reached in at least 50% of the subjects.
157) The method according to any one of embodiments 153) to 155), wherein the reduction from baseline in mSLEDAI-2K is reached in at least 70% of the subjects.
158) The method according to any one of embodiments 89) to 152), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 1 point lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
159) The method according to any one of embodiments 89) to 152), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 1.5 points lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
160) The method according to any one of embodiments 89) to 152), wherein the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) after 12 months treatment of the subjects (especially of subjects having SLE) with either the S1 Pi receptor modulator (especially cenerimod) or placebo is statistically at least 2 points lower in the S1 Pi receptor modulator treated subjects than in placebo treated subjects.
161) The method according to any one of embodiments 89) to 160), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially with cenerimod) is reached in at least 30 % of the subjects.
162) The method according to any one of embodiments 89) to 160), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with the S1 Pi receptor modulator (especially with cenerimod) is reached in at least 50 % of the subjects.
163) The method according to any one of embodiments 89) to 160), wherein a response on SRI-4 after 12 months treatment of the subjects (especially of subjects having SLE) with
the S1Pi receptor modulator (especially with cenerimod) is reached in at least 70 % of the subjects.
164) The method according to any one of embodiments 89) to 160), wherein the probability of a response on SRI-4 after 12 months treatment of a subject (especially of a subject having SLE) is higher (especially statistically significant higher) in a subject treated with the S1 Pi receptor modulator (especially with cenerimod) than in a subject treated with placebo.
165) The method according to any one of embodiments 89) to 164), wherein the time to first confirmation of a 4-month sustained mSLEDAI-2K response (defined as a reduction of at least 4 points from baseline) is shorter (especially statistically significant shorter) in subject(s) treated with the S1 Pi receptor modulator (especially with cenerimod) than in subject(s) treated with placebo.
166) The method according to any one of embodiments 89) to 164), wherein the S1 Pi receptor modulator is cenerimod and wherein the time from treatment onset with cenerimod to first confirmation of a 4-month sustained mSLEDAI-2K response (defined as a reduction of at least 4 points from baseline) is statistically significant shorter in subject(s) treated with cenerimod than in subject(s) treated with placebo.
167) The method according to any one of embodiments 89) to 164), wherein the time to first confirmation of a 4-month sustained response in mucocutaneous manifestations is shorter (especially statistically significant shorter) in subject(s) treated with the S1 Pi receptor modulator (especially with cenerimod) than in subject(s) treated with placebo.
168) The method according to any one of embodiments 89) to 164), wherein the S1 Pi receptor modulator is cenerimod and wherein the time from treatment onset with cenerimod to first confirmation of a 4-month sustained response in mucocutaneous manifestations is statistically significant shorter in subject(s) treated with cenerimod than in subject(s) treated with placebo.
169) The method according to any one of embodiments 89) to 168), wherein the S1 Pi receptor modulator is cenerimod, or a pharmaceutically acceptable salt thereof, and wherein a clinically proven effective amount of cenerimod is administered and/or is to be administered to the subject.
170) The method according to any one of embodiments 89) to 169), wherein the subject is a human (especially a human patient).
171) The method according to any one of embodiments 89) to 169), wherein the subject is a human patient suffering from a type 1 interferon mediated disease.
172) The method according to any one of embodiments 89) to 169), wherein the subject is a human patient suffering from systemic lupus erythematosus and/or lupus nephritis.
173) The method according to any one of embodiments 89) to 169), wherein the subject is a human patient suffering from systemic lupus erythematosus.
174) The method according to any one of embodiments 89) to 169), wherein the subject is a human patient suffering from systemic lupus erythematosus, and wherein the subject has a mSLEDAI-2K score > 6 and a clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
175) The method according to any one of embodiments 89) to 169), wherein the subject is a human patient suffering from systemic lupus erythematosus, and wherein the subject has (i) a mSLEDAI-2K score > 6 and a clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers); (ii) a British Isles Lupus Assessment Group-2004 (BILAG) Grade B in > 2 organ systems or a BILAG Grade A in > 1 organ system; and (iii) Physician's Global Assessment (PGA) score > 1 .0 on a 0 to 3 VAS.
176) The method according to any one of embodiments 89) to 175), wherein the subject is a subject receiving standard background therapy (wherein it is understood that such standard background therapy is suitable for the treatment of a type 1 interferon mediated disease, especially of systemic lupus erythematosus).
177) A further embodiment of the invention relates to a method of treating a type 1 interferon mediated disease (especially systemic lupus erythematosus) in a subject in need thereof, wherein the subject has a high type 1 interferon (IFN-1) gene signature score; the method comprising administering to the subject a pharmaceutical composition comprising a clinically proven effective amount of a S1 Pi receptor modulator (especially cenerimod), or a pharmaceutically acceptable salt thereof.
178) The method according to embodiment 177), wherein the S1 Pi receptor modulator is cenerimod and wherein said clinically proven effective amount of cenerimod is 4.0 mg per day.
179) The method according to any one of embodiments 177) or 178), wherein said method comprises administering to the subject a pharmaceutical composition comprising a clinically proven safe and clinically proven effective amount of the S1 Pi receptor modulator (especially cenerimod).
As used herein, unless otherwise noted, the term "clinically proven" (used independently or to modify the terms "safe" and/or "effective") shall mean that it has been proven by a clinical trial wherein the clinical trial has met the approval standards of U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or a corresponding national regulatory agency. For example, the clinical study may be an adequately sized, randomized, double-blinded study used to clinically prove the effects of the drug.
The term "clinically proven effective" as used herein in the context of a dose, dosage regimen, treatment or method refers to the effectiveness of a particular dose, dosage or treatment regimen. Efficacy can be measured based on change in the course of the disease in response to an agent of the present invention. For example, a S1Pi receptor modulator (especially cenerimod) is administered to a subject in an amount and for a time sufficient to induce an improvement, preferably a sustained improvement, in at least one indicator that reflects the severity of the disorder that is being treated. Various indicators that reflect the extent of the subject's illness, disease or condition can be assessed for determining whether the amount and time of the treatment is sufficient. Such indicators include, for example, clinically recognized indicators of disease severity, symptoms, or manifestations of the disorder in question. The degree of improvement generally is determined by a physician, who can make this determination based on signs, symptoms, biopsies, or other test results, and who can also employ questionnaires that are administered to the subject, such as quality-of-life or patient-reported outcome questionnaires developed for a given disease. For example, a compound of the present invention can be administered to achieve an improvement in a subject's condition related to systemic lupus erythematosus. Improvement can be indicated by an improvement in an index of disease activity, by amelioration of clinical symptoms or by any other measure of disease activity.
In a particular embodiment, such measure of disease activity is the modified systemic lupus erythematosus disease activity index 2000 as compared to baseline and/or as compared to placebo.
In another particular embodiment, such measure of disease is the Systemic Lupus Erythematosus Responder Index (SRI-4) as compared to baseline and/or as compared to placebo.
In another particular embodiment, such measure of disease is the time to first confirmation of a 4-month sustained mSLEDAI-2K response (defined as a reduction of at least 4 points from baseline) as compared to placebo.
In another particular embodiment, such measure of disease is the time to first confirmation of a 4-month sustained response in mucocutaneous manifestations as compared to placebo.
In certain embodiments, a clinically proven effective amount of cenerimod is an amount that results in a reduction in the modified systemic lupus erythematosus disease activity index 2000 as compared to baseline and/or as compared to placebo; as demonstrated via clinical trial having the protocol as described in the “Opus Study Overview” herein below.
The term "clinically proven safe," as it relates to a dose, dosage regimen, treatment or method with the compound of the present invention, cenerimod, refers to a favorable risk:benefit ratio with an acceptable frequency and/or acceptable severity of treatment- emergent adverse events (referred to as AEs or TEAEs). As used herein, "adverse event", "treatment-emergent adverse event", and "adverse reaction" mean any harm, unfavorable, unintended, or undesired sign or outcome associated with or caused by administration of a pharmaceutical composition or therapeutic. It is an untoward medical occurrence in a subject administered a medicinal product.
Abbreviations:
BICLA British Isles Lupus Assessment Group-based Composite Lupus
Assessment
BILAG British Isles Lupus Assessment Group
CT Computed tomography
DNA Deoxyribonucleic acid
ECG Electrocardiogram
EDTA Ethylenediaminetetraacetic acid
FDA U.S. Food and Drug Administration
ICF Informed Consent Form
IFN Interferon
IFNAR Interferon alpha receptor
IFNGR Interferon gamma receptor i.v. intravenous(ly)
JAK Janus kinase
(m)SLEDAI-2K (modified) Systemic lupus erythematosus disease activity index 2000
NSAID Non-steroidal anti-inflammatory drug(s)
(O)CS (oral) Corticosteroid(s)
PCR Polymerase chain reaction
PD (response) Pharmacodynamic (response)
PGA (score) Physician’s Global Assessment (score)
RFU Relative Fluorescence Unit(s)
RNA Ribonucleic acid
SLE Systemic lupus erythematosus
SRI Systemic Lupus Erythematosus Responder Index
SRI-4 SRI with an improvement from baseline of at least 4 points in the mSLEDAI-2K
STAT Signal transducer and activator of transcription
TYK Tyrosine kinase
ULN Upper Limit of Normal
VAS Visual analogue scale (VAS).
Experimental Part
In the Phase 2b clinical study (CARE), the placebo cohort and cenerimod 4 mg cohort distribution of the IFN-1 gene expression signature score was measured (Figure 1A). A bimodal distribution was observed and a cut-off of -0.5 was used to separate IFN high from IFN low patients. Surprisingly, there was a strong reduction in the IFN score after 6 months treatment with cenerimod 4 mg compared to placebo (figure 1 B). Upon subgroup analysis of patients categorized as IFN high and IFN low at baseline unexpectedly, only a reduction in mSLEDAI-2K to baseline was observed in the IFN high subgroup, (figure 1C). In the IFN- 1 high patient subgroup, a larger change from baseline in mSLEDAI-2K was observed in the 4 mg group compared to placebo with a least square LS-Means (SE) change from baseline to month 6 of -2.6 for placebo and -5.4 for cenerimod 4 mg (figure 1C). This improvement in mSLEDAI-2K in IFN-1 high patients was seen even though reductions in blood lymphocyte counts were observed to an equal extend both in IFN-1 low and high patients (figure 2), suggesting that lymphocyte reduction is not predictive of mSLEDAI-2K reduction.
Further cenerimod reduces both the IFN-1 gene signature score and IFN-oc protein in the plasma of patients treated with cenerimod (Figure 3A) both of which are more abundant in patients with SLE compared to healthy volunteers (figure 3B). Patients with high IFN-oc protein levels at baseline display a larger reduction in the mSLEDAI-2K score as compared to the IFN alpha protein low cohort (figure 3C). In addition, cenerimod 4 mg reduces IFN gamma protein in plasma at 6 months compared to baseline and compared to placebo (Figure 4A), which also is more abundant in patients with SLE compared to healthy volunteers (figure 4B). Patients with high IFN gamma protein levels at baseline display a larger reduction in the mSLEDAI-2K score as compared to the IFN gamma protein low cohort (figure 4C).
Importantly the IFN-1 gene signature score correlated with the measured IFN alpha plasma protein values (figure 5A) at baseline strengthening the validity of the IFN gene signature score as a readout of IFN alpha protein. Additionally, cenerimod 4 mg leads to a reduction in the IFN-1 score in both IFN-1 high and IFN-1 low patients at 6 months compared to baseline which is not observed in placebo (figure 5B). Surprisingly, despite cenerimod 4 mg lowering the IFN score in all patients equally, the reduction on mSLEDAI-2K is only apparent in IFN-1 high patients.
Gene expression signature
A modulation of biological activity is reflected in changes of gene expression. These changes can be described by specific gene expression signatures. A gene signature is defined by a set of genes that show increased or decreased expression upon the biological activity. Gene signatures are most often analyzed using quantitative reverse transcription PCR (RT-qPCR), which allows standardized expression levels for each gene of interest to be derived.
The IFN-1 signature reflects IFN-regulated genes, meaning that those genes are upregulated due to the biological activity of type 1 IFNs. An IFN-1 gene signature was first described in 2003 in cells isolated from patients with SLE [Baechler, EC. et al., PNAS 2003, 100(5), 2610-2615, PMID:12604793],
An important property of the IFN-1 gene signature is the bimodal distribution in patients with SLE allowing separation into high or low IFN-1 gene signature strata [El-Sherbiny, YM. et al., Scientific Reports 2018, 8, 5793, DOI :10.1038/s41598-018-24198-1 , PMID: 29643425], There are two most used IFN-1 gene signatures in clinical studies (AstraZeneca [AZ] and DxTerity signature). Although both signatures comprise 4 genes, the difference is in the selection of genes. Both signatures contain IFI27 and RSAD2, but
AZ includes in addition IFI44 and IFI44L, whereas DxTerity uses IFIT1 and HERC5. Importantly, the two IFN-1 gene signatures correlate very well and will therefore classify the SLE patients in the same high and low strata as long as the cut-off is derived in the same way. It was previously shown different IFN-1 gene signatures will classify patients into the same IFN-1 status (Abedi M, Comparison Of Different Type 1 IFN Signatures Demonstrates Concordance In A Real World, Home Monitored Systemic Lupus Erythematosus Cohort, EULAR 2018, poster #SAT0041).
The DxTerity gene expression assay contains ten interferon genes (EIF2AK2, HERC5, IFI27, IFI44, IFI44L, IFI6, IFIT1 , ISG15, MX1 , RSAD2). Four of those genes (HERC5, IFIT1 , IFI27, and RSAD2) are used in the IFN-1 test to define the IFN-1 gene signature status (high/low). The assay is using a proprietary Chemical Ligation-dependent Probe Amplification (CLPA/DxDirect) technology.
The DxTerity signature cut-off point of -0.5 (for differentiating IFN high and low subjects) is based on the 95th percentile of more than 500 healthy human (Figure 1A), while the AZ cut-off point would lead to more than 10% of healthy subjects being classified as high.
Each target gene expression level is normalized to three housekeeping (normalizer) genes (ACTB, GAPDH, and TFRC). The gene expression level of each individual subject is calculated from the capillary electrophoresis electropherogram using the intensity of the fragment peak height (RFU) corresponding to the 4 interferon responsive genes relative to the average of the intensities of three normalizer gene peak heights (from the same subject) using the following formula:
Normalized Expression Gene i = Log2 (Height Gene i) - Mean (Log2 (Normalizer Genes Height))
The IFN-1 gene signature score of the subject is determined by averaging the normalized expression values of the HERC5, IFI27, IFIT1 , and RSAD2 genes.
The high/low cut-off (-0.5) is based on the 95th percentile of more than 500 healthy human and is placed 2 standard deviations above the mean IFN-1 gene signature score of the healthy volunteers, and it falls in the trough of the classic bimodal IFN-1 gene signature score distribution seen for SLE patients.
Plasma proteins
Interferon alpha (IFNa or IFN-a) was measured in EDTA plasma using an ELISA assay from PBL assay science (41115) following the instructions provided by the supplier. Normal IFNa levels are below the detection limit of the assay (0.1 pg/ml). The high/low cut-off is based on the 95th percentile of 10 healthy human volunteers (Figure 3B).
Interferon gamma (IFNg or IFN-y) was measured in EDTA plasma using a V-plex assay from Mesoscale discovery (K151A9H-2) following the instructions provided by the supplier. Normal IFNg levels are reported to be 3.80 pg/ml (median, n=27, 0.46 - 22.8 pg/ml). As comparison, in-house measurement of 10 EDTA plasma samples from healthy volunteers showed median levels of 1.49 pg/ml (0.49 - 12.28 pg/ml). The high/low cut-off is based on the 95th percentile of 10 healthy human volunteers (Figure 4B).
CARE study overview
The study design was a double-blind randomized placebo-controlled study in patients with SLE. A total of 85 patients were included in the 4mg cenerimod arm and 86 patients in the placebo arm.
At the time of drug initiation 4 mg cenerimod and placebo, defined as baseline, 12.5ml of blood were taken via standard venipuncture by the study nurse and collected in PAX-gene tubes for the subsequent assessment of the IFN gene signature. Tubes containing blood were frozen and remained frozen until further use. EDTA plasma was prepared from blood by standard protocol.
At baseline 36 patients were classified as IFN-1 high and 44 as IFN-1 low in the 4mg cenerimod arm. In the placebo arm 40 patients were classified as IFN-1 high and 40 patients as IFN-1 low.
The Study design and key inclusion criteria were the following:
The primary objective of the study was to assess the efficacy of 6 months of cenerimod at 4 mg in subjects with moderate to severe SLE. Secondary and exploratory objectives (6 months) included, but not limited, were to the effect on SLE biomarkers and exploratory biomarkers, to assess safety and tolerability of cenerimod doses, to assess the effect on quality of life and fatigue using patient reported outcome (PRO) instrument and to assess the effect on SLE biomarkers.
The inclusion criteria were as follows: A Diagnosis of SLE made at least 6 months prior to Screening (at least 4 ACR criteria), a modified SLEDAI-2K (mSLEDAI-2K) score > 6 of at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers) at screening. The modified SLEDAI-2K is defined as SLEDAI-2K with the removal of leukopenia which is one of the scores utilized in the SLEDAI-2K composite score. SLEDAI-2K is described elsewhere (Gladman et al, J Rheumatol. 2002 Feb;29(2):288-91). A clinical mSLEDAI-2K score > 4 at randomization was required. Further, a positive Antinuclear Antibody test (ANA) with titre >1 :80 (by immunofluorescence assay) AND/OR positive anti-dsDNA with titre >30 lU/mL at
randomization was required. Participants had to be on a stable background SLE medication for a period of at least 30 days (15 days for corticosteroids) prior to randomization. Participants if using Corticosteroids had to have < 40 mg/day prednisone or equivalent. Women of childbearing potential (WOCBP) must have agreed to use highly effective methods of contraception.
The exclusion criteria were the following: Patients having active lupus nephritis (defined by proteinuria > 1 .5 g/24 h, or equivalent using spot urine protein-to-creatinine ratio) or a renal biopsy demonstrating immune complex-mediated glomerulonephritis compatible with lupus nephritis. Patients exhibiting CNS lupus (e.g., aseptic meningitis, seizures, cerebritis, polyneuropathy, cerebrovascular disease, organic brain syndrome) and severe forms of vasculitis requiring systemic immunosuppressive treatment (e.g., retinal vasculitis, coronary vasculitis, pulmonary vasculitis, mesenteric vasculitis) within 90 days prior to screening. Patients presenting with a diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with rheumatoid arthritis, erosive arthritis, scleroderma, or autoimmune hepatitis.
The Study treatment was the following: A daily tablet of cenerimod or placebo was taken orally irrespective of food intake and preferably in the morning.
Background therapy criteria: Subjects received at least one of the below listed SLE background medication and had to be stable 30 days prior to randomization except for Oral Corticosteroids (OCS) (which should be stable for at least 15 days prior randomization) NSAIDs: Aspirin (acetylsalicylic acid), Ibuprofen, Naproxen, Celecoxib, Other NSAIDs, Prednisone or equivalent < 40 mg/day, anti-malaria’s: Hydroxychloroquine, Chloroquine, Quinacrine, Mycophenolate mofetil, Mycophenolic acid, Azathioprine, Methotrexate, Belimumab must have started at least 30 days prior to Screening. After Randomization, background therapy was kept stable throughout the study. However, if clinically relevant, changes were allowed as follows: Chronic NSAID therapy not to be started or stopped during the study but temporary use and/or dose change for treatment of non-SLE-related conditions (e.g., headache, menstrual cramps) was allowed. Further, immunosuppressant therapy (i.e., methotrexate, azathioprine, mycophenolate mofetil, mycophenolic acid, belimumab) was not started or stopped during the study and the dose was kept stable. Atropine was used (i.v.) in the event of symptomatic bradycardia.
The primary efficacy endpoint is the change from baseline to Month 6 in the modified SLEDAI-2K score. Further secondary endpoints were:
Response on SRI-4 as defined previously (Furie R: et al Arthritis Rheum. 2009 Sep 15;61 (9):1143-51) at Month 6 as compared to baseline, defined as follows:
Reduction from baseline of at least 4 points in the mSLEDAI-2K; AND
No new organ system affected as defined by one or more BILAG A or 2 or more BILAG B as defined previously (Romero-Diaz J et al Arthritis Care Res (Hoboken). 2011 Nov; 63 Suppl 11 (0 11):S37-46. doi: 10.1002/acr.20572.) items as compared to baseline; AND
No increase of more than 0.3 points on the Physician's Global Assessment (PGA) since baseline. The Physician Global Assessment (PGA) is a visual analog scale (VAS) using 3 benchmarks for assessing disease activity over the last 2 weeks (Luijten KMAC et al, Autoimmunity Reviews Volume 11 , Issue 5, March 2012, Pages 326-329). Mild flare will score 1.0 point, moderate flares will score a 2.0-2.5 point and severe flares will score a 3 on the 0-3 analog scale.
Further, the percent of subjects with no new organ system affected as defined by one or more BILAG A or 2 or more BILAG B items as compared with baseline.
Opus Study Overview
The Opus studies are two phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects (18 years to 75 years) with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy. Subjects are randomized 1 :1 to either cenerimod or matching placebo. Cenerimod is supplied once daily in addition to background SLE therapy as film-coated tablets at the dose of 4 mg.
Primary Outcome Measures:
1. Change from baseline to Month 12 in the modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) score (Time Frame: Day 1 (pre-dose baseline) to Month 12).
This endpoint is based on the SLEDAI-2K index, modified to exclude leukopenia. All values of mSLEDAI-2K from baseline through Month 12 visits are accounted for in the assessment of this endpoint.
Secondary Outcome Measures:
1. Response on Systemic Lupus Erythematosus Responder Index (SRI-4) at Month 12 (Time Frame: Day 1 (pre-dose baseline) to Month 12).
Response on SRI-4 is defined as: o Reduction from baseline of at least 4 points in the mSLEDAI-2K, and
o No new British Isles Lupus Assessment Group-2004 (BILAG) A organ domain score and not more than one new BILAG B organ domain score compared to baseline, and o No worsening from baseline in subjects' lupus disease activity, where worsening is defined as an increase > 0.30 points on a 3-point Physician's Global Assessment visual analog scale, and o No violation of protocol-specified medication rules detailed in the core protocol.
2. Time to first confirmation of a 4-month sustained modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) response (Time Frame: Day 1 (pre-dose baseline) to Month 12).
A response is defined as a reduction of at least 4 points from baseline.
3. Time to first confirmation of a 4-month sustained response in mucocutaneous manifestations (Time Frame: Day 1 (pre-dose baseline) to Month 12).
Response is defined as: o No increase in the overall mSLEDAI-2K score, and o Remission (score of zero) from baseline in the mSLEDAI-2K score of mucocutaneous manifestations.
Inclusion Criteria:
Inclusion criteria at screening:
Signed Informed Consent Form (ICF) prior to any study-mandated procedure. Diagnosis of Systemic Lupus Erythematosus (SLE) made at least 6 months prior to Screening, according to 2019 European League Against Rheumatism I American College of Rheumatology Criteria.
- An modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) score > 6 and clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). The mSLEDAI-2K score does not include “leukopenia”.
British Isles Lupus Assessment Group-2004 (BILAG) Grade B in > 2 organ systems or a BILAG Grade A in > 1 organ system.
Physician's Global Assessment (PGA) score > 1.0 on a 0 to 3 Visual Analogue Scale (VAS).
- Currently treated with one or more of the following SLE background medications: o Anti-malarials (< 400 mg/day hydroxychloroquine, < 500 mg/day chloroquine, < 100 mg/day quinacrine).
o Mycophenolate mofetil (< 2 g/day) / mycophenolic acid (<1 .44 g/day). o Azathioprine (< 2 mg/kg/day). o Methotrexate (< 25 mg/week). o Oral Corticosteroids (OCS):
■ if OCS is the only SLE background medication: > 7.5 mg/day and <30 mg/day prednisone or equivalent.
■ if OCS is not the only SLE background medication: < 30 mg/day prednisone or equivalent. o Belimumab (<10 mg/kg every 4 weeks intravenously, or 200 mg/week subcutaneously (s.c.).
Treatment with antimalarials, mycophenolate mofetil, mycophenolic acid, azathioprine, methotrexate or belimumab must have been started at least 90 days prior to Screening. Treatment with OCS must have been started at least 30 days prior to Screening.
For women of childbearing potential (WoCBP): o Negative serum pregnancy test at Screening. o Agreement to undertake monthly urine pregnancy tests from Randomization up to 6 months after study treatment discontinuation. o Agreement to use a highly effective method of contraception from Screening (Visit 1) up to 6 months after study treatment discontinuation.
Inclusion criteria at randomization:
- A clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
British Isles Lupus Assessment Group-2004 (BILAG) Grade B in 2 or more organ systems or a BILAG Grade A in 1 or more organ system.
Physician's Global Assessment (PGA) score > 1 .0 on a 0 to 3 visual analog scale.
Presence of at least one of the following items of serological evidence of active SLE or biological variables predictive of Type 1 Interferon (IFN-1) high signature (in a Screening sample as measured by central laboratory): o Anti-dsDNA antibodies elevated to above normal. o Complement C3 < lower limit of normal. o Antinuclear Antibodies with a titer of at least 1 : 160. o Anti-Smith antibody elevated to above normal. o Platelets < 200 000/pL.
o Urine protein/creatinine ratio > 12.5 mg/mmol (110.5 mg/g).
- Currently treated with one or more of the following SLE background medications that must be stable for at least 30 days prior to Randomization (except OCS, which must be stable for at least 15 days prior to Randomization): o Antimalarials (< 400 mg/day hydroxychloroquine, < 500 mg/day chloroquine, < 100 mg/day quinacrine). o Mycophenolate mofetil (< 2 g/day) I mycophenolic acid (< 1 ,44g/day). o Azathioprine (< 2 mg/kg/day). o Methotrexate (< 25 mg/week). o OCS:
■ if OCS is the only SLE background medication: > 7.5 mg/day and < 30 mg/day prednisone or equivalent.
■ if OCS is not the only SLE background medication: < 30 mg/day prednisone or equivalent). o Belimumab (< 10 mg/kg every 4 weeks intravenous (i.v.) or < 200 mg/week s.c.).
- WoCBP must have a negative urine pregnancy test at Randomization.
Main Exclusion Criteria:
Pregnant, planning to be become pregnant up to Final Study Visit or lactating women.
- Severe central nervous system lupus or active severe or unstable neuropsychiatric SLE characterized by: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; or mononeuritis multiplex: o That would make the subject unable to fully understand the ICF; OR o Where, in the opinion of the Principal Investigator, protocol-specified standard of care is insufficient and the use of a more aggressive therapeutic approach, such as adding i.v. cyclophosphamide and/or high dose i.v. pulse corticosteroid (CS) therapy or other treatments not permitted in the protocol is indicated.
- A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with psoriasis, rheumatoid arthritis, erosive arthritis, scleroderma, autoimmune hepatitis, or uncontrolled autoimmune thyroid disease.
History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders.
- Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the New York Heart Association Class lll/IV within 6 months prior to Screening.
Resting Heart Rate < 50 bpm as measured by the 12-lead ECG at Screening or at Randomization.
- An elevated QT interval corrected according to Fridericia's formula (QTcF) interval of > 470 ms (females) I > 450 ms (males) at Screening or at Randomization.
History or presence of severe respiratory disease or pulmonary fibrosis, based on medical history and chest X-ray (or CT scan as per local guidelines), performed at Screening or within 6 months prior to Screening.
History of clinically relevant bronchial asthma or chronic obstructive pulmonary disease that has required treatment with oral or parenteral CS for more than a total of 2 weeks within the last 6 months prior to Screening.
History or presence of malignancy (except for surgically excised basal or squamous cell skin or mucosal lesions, including dysplasia and carcinoma in situ), lymphoproliferative disease, or history of total lymphoid irradiation.
Presence of macular edema or active uveitis detected by optical coherence tomography (OCT) during screening.
History of chronic liver or biliary disease (other than Gilbert's Syndrome) or subjects with alanine aminotransferase or aspartate aminotransferase > 3 x Upper Limit of Normal (ULN) or total bilirubin > 1.5 ULN (unless in the context of known Gilbert's Syndrome).
Significant hematology abnormality at screening assessment: o lymphocyte count < 500 /pL (0.5 x 10A9/L) ; o hemoglobin < 7 g/dL; o white blood cell count < 2000/pL (2.0 x 10A9/L); or o platelets < 25000/pL (25 x 10A9/L) at screening assessment.
- Treatment with the following medications within 15 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: o p-blockers, diltiazem, verapamil, digoxin, digitoxin, or any other antiarrhythmic or heart-rate -lowering systemic therapy. o QT-prolonging drugs with known risk of torsade de pointes irrespective of indication.
- Treatment with the following medications within 30 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: o Cyclophosphamide, cyclosporine, tacrolimus, sirolimus, mizoribine, etc. o Pulse methylprednisolone. o Vaccination with live vaccines (including live vaccines for COVID-19).
I ntra-articular, intramuscular or i.v. CS within 6 weeks prior to Randomization.
- Treatment with the following medications within 90 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: o Leflunomide. o i.v. immunoglobulins.
- Treatment with any investigational agent within 90 days or 5 half-lives of the drug (whichever is longer) prior to Randomization.
- Treatment with B cell-depleting biological agents, e.g., rituximab or ocrelizumab, within 12 months prior to Randomization.
- Treatment with anifrolumab within 12 months prior to Randomization.
- Treatment with any of the following medications any time prior to Screening: o Alemtuzumab. o Sphingosine-1-phosphate receptor modulators (e.g., fingolimod). o Subjects previously randomized to cenerimod or placebo in any trial involving cenerimod.
Claims
1 . A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a type 1 interferon mediated disease in a subject, wherein the subject has a high type 1 interferon (IFN-1) gene signature score.
2. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to claim 1 , wherein the type 1 interferon gene signature score is calculated based on any one of the following groups of type 1 interferon-associated genes: a. RSAD2, IFI44, IFI44L, and IFI27; or b. RSAD2, IFI27, IFIT1 , and HERC5.
3. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 or 2, wherein the type 1 interferon gene signature score of the subject is at or above the minimum of the bimodal distribution curve of the type 1 interferon gene signature scores of SLE patients.
4. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 or 2, wherein the type 1 interferon gene signature score of the subject is above a threshold value, wherein the threshold value of the IFN-1 gene signature score is 2 standard deviations above the arithmetic mean value from at least 100 healthy humans.
5. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in a method of preventing or treating a subject having a type 1 interferon mediated disease, the method comprising: a) providing a biological sample from the subject; b) assaying gene expression of at least three type 1 interferon-associated genes selected from the group consisting of DHX58, EIF2AK2, IRF7, PARP9, SAMD9L, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1, IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6 (especially IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, ISG15, LAMP3, OAS3, OAS1 , EPSTI1 , IFIT3, LY6E, OAS2, PLSCR1 , SIGLEC1 , USP18, RTP4, and DNAPTP6, and notably EIF2AK2, IFI6, RSAD2, IFI44, IFI44L, IFI27, MX1 , IFIT1 , HERC5, and ISG15) in the biological sample; c) determining a normalised expression value of each assayed gene; d) calculating a type 1 interferon gene signature score by averaging the normalised expression values; and
e) treating the subject with the S1 Pi receptor modulator when the type 1 interferon gene signature score of the subject is higher than a threshold value.
6. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to claim 5, wherein one of the following groups of type 1 interferon- associated genes is selected for assaying gene expression: a) RSAD2, IFI44, IFI44L, and IFI27; or b) RSAD2, IFI27, IFIT1 , and HERC5.
7. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a type 1 interferon mediated disease in a subject, wherein the concentration/level of interferon-gamma (IFN-y) in the subject is elevated compared to a healthy subject.
8. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 7, wherein the subject has a concentration/level of interferon-alpha (IFN-a ) above 0.1 pg/mL and/or of interferon-gamma (IFN-y) above 9.5 pg/mL.
9. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 8, wherein the S1 Pi receptor modulator is selected from ozanimod, siponimod, ponesimod, cenerimod, etrasimod, mocravimod and amiselimod, or a pharmaceutically acceptable salt thereof.
10. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 8, wherein the S1 Pi receptor modulator is cenerimod.
11. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to claim 10, wherein cenerimod is to be administered and/or is administered to a subject for a treatrment period of at least 6 months.
12. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 11 , wherein type 1 interferon mediated disease is selected from the group consisting of systemic lupus erythematosus, discoid lupus, lupus nephritis, glomerulonephritis, type I diabetes, inflammatory bowel disease (including Crohn’s disease, ulcerative colitis, and Celiac’s disease), multiple sclerosis, autoimmune thyroiditis, scleroderma, psoriasis, primary Sjogren’s disease, systemic sclerosis, rheumatoid arthritis, transplant rejection, dermatomyositis, polymyositis, idiopathic inflammatory myositis, sarcoidosis, Aicardi- Goutieres syndrome, vasculitis, Sting associated vasculopathy with onset in infancy (SAVI) or chronic atypical neutrophilic dermatosis with lipodystrophy and elevanted temperature syndrome (CANDLE).
A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 11 , wherein type 1 interferon mediated disease is systemic lupus erythematosus. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 13, wherein a reduction from baseline in the modified systemic lupus erythematosus disease activity index 2000 (mSLEDAI-2K) is reached after 12 months treatment of the subject with cenerimod. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 14, wherein the subject is a human patient suffering from systemic lupus erythematosus. A S1 Pi receptor modulator, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 14, wherein the subject is a human patient suffering from systemic lupus erythematosus, and wherein the subject has a mSLEDAI-2K score > 6 and a clinical mSLEDAI-2K score > 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263375668P | 2022-09-14 | 2022-09-14 | |
US63/375,668 | 2022-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024056631A1 true WO2024056631A1 (en) | 2024-03-21 |
Family
ID=88093165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/074961 WO2024056631A1 (en) | 2022-09-14 | 2023-09-12 | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024056631A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011007324A1 (en) | 2009-07-16 | 2011-01-20 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
WO2011028933A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
WO2013175397A1 (en) | 2012-05-22 | 2013-11-28 | Actelion Pharmaceuticals Ltd | New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid |
WO2016184939A1 (en) | 2015-05-20 | 2016-11-24 | Actelion Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
WO2020084591A1 (en) | 2018-10-26 | 2020-04-30 | Janssen Biotech, Inc. | Type i interferon signatures and methods of use |
WO2022074123A1 (en) | 2020-10-08 | 2022-04-14 | Astrazeneca Ab | Treatment of flares in lupus |
-
2023
- 2023-09-12 WO PCT/EP2023/074961 patent/WO2024056631A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011007324A1 (en) | 2009-07-16 | 2011-01-20 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
WO2011028933A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
WO2013175397A1 (en) | 2012-05-22 | 2013-11-28 | Actelion Pharmaceuticals Ltd | New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid |
WO2016184939A1 (en) | 2015-05-20 | 2016-11-24 | Actelion Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
WO2020084591A1 (en) | 2018-10-26 | 2020-04-30 | Janssen Biotech, Inc. | Type i interferon signatures and methods of use |
WO2022074123A1 (en) | 2020-10-08 | 2022-04-14 | Astrazeneca Ab | Treatment of flares in lupus |
Non-Patent Citations (59)
Title |
---|
"CENTER FOR DRUG EVALUATION AND RESEARCH, BLA 761123 Multi-disciplinary Review and Evaluation, Saphnelo (anifrolumab-fnia) for adults with SLE", FDA SAPHNELO MULTI-DISCIPLINE REVIEW, 12 October 2018 (2018-10-12), pages 44 - 47 |
"Handbook of Pharmaceutical Salts. Properties, Selection and Use", 2008, WILEY-VCH |
"Pharmaceutical Salts and Co-crystals", 2012, RSC PUBLISHING |
ABEDI M ET AL., ANNALS OF THE RHEUMATIC DISEASES, vol. 77, no. 2, 2018, pages 885 - 886 |
ABEDI M. ET AL: "SAT0041?Comparison of different type 1 ifn signatures demonstrates concordance in a real world, home monitored systemic lupus erythematosus cohort", EULAR 2018 EUROPEAN CONGRESS OF RHEUMATOLOGY, 1 June 2018 (2018-06-01), pages 885 - 886, XP093099515, Retrieved from the Internet <URL:https://ard.bmj.com/content/77/Suppl_2/885.3> DOI: 10.1136/annrheumdis-2018-eular.3758 * |
ABEDI M: "Comparison Of Different Type 1 IFN Signatures Demonstrates Concordance In A Real World", HOME MONITORED SYSTEMIC LUPUS ERYTHEMATOSUS COHORT, EULAR, 2018 |
ANONYMOUS CLINICALTRIALS: "NCT03742037 - Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus", CLINICALTRIALS.GOV, 28 July 2022 (2022-07-28), pages 1 - 25, XP093100376, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT03742037?a=39&tab=history> [retrieved on 20231110] * |
BAECHLER, EC ET AL., PNAS, vol. 100, no. 5, 2003, pages 2610 - 2615 |
BURG, N. ET AL., NAT REV RHEUMATOL., vol. 18, no. 6, 2022, pages 335 - 351 |
CASTELLANO, G. ET AL., ARTHRITIS RESEARCH THERAPY, vol. 17, 2015, pages 72 |
CATALINA, MD ET AL., COMMUNICATIONS BIOLOGY, vol. 2, no. 140, 2019 |
CELLA, M. ET AL., NATURE MED, vol. 5, no. 8, 1999, pages 919 - 923 |
COLONNA, M. ET AL., CURRENT OPINION IMMUNOL, vol. 14, 2002, pages 373 - 379 |
DENG, Y. ET AL., CURR RHEUMATOL REP, vol. 19, 2017, pages 68 |
EI-SHERBINY, YM. ET AL., SCIENTIFIC REPORTS, vol. 8, 2018, pages 5793 |
FENG, X. ET AL., ARTHRITIS RHEUMATISM, vol. 54, no. 9, 2006, pages 2951 - 2962 |
FURIE R ET AL., ARTHRITIS & RHEUMATOLOGY, vol. 69, no. 2, 2017, pages 376 - 386 |
FURIE R ET AL., ARTHRITIS RHEUM., vol. 61, no. 9, 15 September 2009 (2009-09-15), pages 1143 - 51 |
FURIE, R. ET AL., ARTHRITIS RHEUMATISM, vol. 61, no. 9, 2009, pages 1143 - 1151 |
GLADMAN DD ET AL., J RHEUMATOL, vol. 29, no. 2, 2002, pages 288 - 291 |
GLADMAN ET AL., J RHEUMATOL., vol. 29, no. 2, February 2002 (2002-02-01), pages 288 - 91 |
HERMANN V ET AL., LUPUS SCIENCE & MEDICINE, vol. 6, 2019, pages e000354 |
HERMANN V ET AL., LUPUS SCIENCE &, vol. 6, 2019, pages e000354 |
HERMANN VIKTORIA ET AL: "First use of cenerimod, a selective S1P 1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study", LUPUS SCIENCE & MEDICINE, 9 November 2019 (2019-11-09), pages 1 - 21, XP093099087, Retrieved from the Internet <URL:https://lupus.bmj.com/content/6/1/e000354> [retrieved on 20231108], DOI: 10.1136/lupus-2019-000354 * |
KALUNIAN, K. ET AL., ANN RHEUM DIS, vol. 75, 2016, pages 196 - 202 |
KENNEDY, WP. ET AL., LUPUS SCI MED, vol. 2, 2015, pages e000080 |
KIROU, K. ET AL., ARTHRITIS & RHEUM., vol. 52, no. 5, 2005, pages 1491 - 1503 |
KIROU, KA ET AL., ARTHRITIS RHEUMATISM, vol. 50, no. 12, 2004, pages 3958 - 3967 |
KIROU, KA ET AL., ARTHRITIS RHEUMATISM, vol. 52, no. 5, 2005, pages 1491 - 1503 |
LANDOLT-MARTICORENA, C. ET AL., ANN RHEUM DIS, vol. 68, 2009, pages 1440 - 1446 |
LEE-KIRSCH, MA., ANNU REV MED, vol. 68, 2017, pages 297 - 315 |
LIPSKY, PE ET AL., ANN RHEUM DIS, vol. 81, 2022, pages 1136 - 1142 |
LUIJTEN KMAC ET AL., AUTOIMMUNITY REVIEWS, vol. 11, no. 5, March 2012 (2012-03-01), pages 326 - 329 |
MAI, L. ET AL., ARTHRITIS RESEARCH THERAPY, vol. 23, 2021, pages 29 |
MCNAB, F. ET AL., NAT REV IMMUNOL, vol. 15, 2015, pages 87 - 103 |
MENDELSON, K. ET AL., DEVELOPMENT, vol. 141, 2014, pages 5 - 9 |
MERRILL, JT. ET AL., N ENGL J MED, vol. 386, 2022, pages 1034 - 1045 |
NIEWOLD, T ET AL., GENES AND IMMUNITY, vol. 8, 2007, pages 492 - 502 |
NORTHCOTT M ET AL., LUPUS SCIENCE & MEDICINE, vol. 9, 2022, pages e000625 |
NORTHCOTT, M. ET AL., LANCET RHEUMATOLOGY, vol. 3, no. 5, 2021, pages e357 - e370 |
NORTHCOTT, M. ET AL., LUPUS SCI MED, vol. 9, 2022, pages e000625 |
OKE, V. ET AL., ARTHRITIS RESEARCH THERAPY, vol. 21, 2019, pages 107 |
PETRI, M. ET AL., ARTHRITIS RHEUMATISM, vol. 65, no. 4, 2013, pages 1011 - 1021 |
PLATANIAS, LC., NAT REV IMMUNOL, vol. 5, 2005, pages 375 - 386 |
PSARRAS, A. ET AL., RHEUMATOLOGY, vol. 56, 2017, pages 1662 - 1675 |
R.C. ROWEP.J. SESKEYS.C. OWEN: "Handbook of Pharmaceutical Excipients", 2006, PHARMACEUTICAL PRESS |
RAHMAN, A. ET AL., N ENGL J MED, vol. 358, 2008, pages 929 - 939 |
RBNNBLOM, L. ET AL., CURR OPIN RHEUMATOL, vol. 25, no. 2, 2013, pages 248 - 253 |
REMINGTON: "The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS, article "Pharmaceutical Manufacturing" |
ROMERO-DIAZ J ET AL., ARTHRITIS CARE RES (HOBOKEN, vol. 63, no. 11, November 2011 (2011-11-01), pages 37 - 46 |
RONNBLOM, L. ET AL., LUPUS SCI MED, vol. 6, 2019, pages e000270 |
SHIOW, L. ET AL., NATURE, vol. 440, 2006, pages 540 - 544 |
STRASSER D ET AL: "Supplementary material and methods - files 1-5", RMD OPEN (ONLINE SUPPLEMENTAL SECTION), 11 September 2020 (2020-09-11), pages 1 - 18, XP093099895, Retrieved from the Internet <URL:https://rmdopen.bmj.com/content/6/2/e001261> [retrieved on 20231109] * |
STRASSER DANIEL S ET AL: "Preclinical to clinical translation of cenerimod, a novel S1P 1 receptor modulator, in systemic lupus erythematosus", RMD OPEN, 1 September 2020 (2020-09-01), pages 1 - 12, XP093099480, Retrieved from the Internet <URL:https://rmdopen.bmj.com/content/6/2/e001261> [retrieved on 20231108], DOI: 10.1136/rmdopen-2020-001261 * |
STRASSER, DS ET AL., RMD OPEN, vol. 6, 2020, pages e001261 |
TEIJARO, JR. ET AL., CELL, vol. 146, no. 6, 2011, pages 980 - 991 |
TEIJARO, JR. ET AL., PNAS, vol. 113, no. 5, 2016, pages 1351 - 1356 |
WESTRA H-J ET AL., NATURE GENETICS, vol. 45, no. 10, 2013, pages 1238 - 1243 |
YAO Y ET AL., HUMAN GENOMICS AND PROTEOMICS, no. 374312, 2009 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Piehl | Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis | |
Yellin et al. | A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis | |
Udalova et al. | Anti-TNF therapy | |
JP2018008951A (en) | METHODS OF TREATMENT USING ANTIBODY AGAINST INTERFERON-γ | |
EP2332408B1 (en) | Treating neurological disorders | |
JP2023090964A (en) | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers | |
Gensicke et al. | Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis | |
US12009079B2 (en) | Type I interferon signatures and methods of use | |
TW201307845A (en) | Predictive methods and methods of treating arthritis using IL-17 antagonists | |
AU2004266111B8 (en) | Compositions and methods for treatment of Severe Acute Respiratory Syndrome (SARS) | |
JP2014516970A (en) | Methods of treating systemic lupus erythematosus, scleroderma, and myositis with antibodies to interferon-α | |
JPWO2018025923A1 (en) | Anti-HTLV-1 agent, HTLV-1-related myelopathy (HAM / TSP) therapeutic agent | |
JP2023549872A (en) | steroid saving | |
WO2024056631A1 (en) | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases | |
US9139879B2 (en) | TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease | |
TW202416967A (en) | S1p1receptor modulators for use in the treatment of type 1 ifn mediated diseases | |
K Paap et al. | An inventory of short term and long term changes in gene expression under interferon β treatment of relapsing remitting MS patients | |
JP2023527054A (en) | Treatment of cardiometabolic disease with inhibitors of type I interferon signaling | |
KR20210060582A (en) | Pan-ELR+ CXC chemokine antibody for the treatment of purulent sweating | |
CN112823007A (en) | Treatment of primary biliary and primary sclerosing cholangitis with baricitinib | |
WO2020039401A1 (en) | Treatment comprising il-1βeta binding antibodies and combinations thereof | |
US20230374124A1 (en) | Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof | |
Cunningham et al. | Ultrarare Variants in DNA Damage Repair Genes in Pediatric Acute-Onset Neuropsychiatric Syndrome or Acute Behavioral Regression in Neurodevelopmental Disorders | |
Ricordi et al. | Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? | |
Inoue et al. | Mechanism to develop inflammasome-independent and interferon-β-resistant EAE with neuronal damages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23772150 Country of ref document: EP Kind code of ref document: A1 |